title,phrase
US - Osimertinib - SA4_WarningsPrecautions_Procedures_Surgery,Do I need to hold Tagrisso for surgery?
US - Osimertinib - SA4_WarningsPrecautions_Procedures_Surgery,stop tagrisso for surgery
US - Osimertinib - SA4_WarningsPrecautions_Procedures_Surgery,surgery and tagrisso
US - Olaparib - RE4_PUBLISHEDDATA_DUO-E_SAFETY,DUO-E Safety
US - Olaparib - RE4_PUBLISHEDDATA_DUO-E_SAFETY,Safety of DUO-E
US - Olaparib - RE4_PUBLISHEDDATA_DUO-E_SAFETY,Safety results DUO-E
US - Olaparib - RE4_PUBLISHEDDATA_DUO-E_SAFETY,Safety in DUO-E
US - Durvalumab - RE3_PublishedData_DUO-O,DUO-O
US - Durvalumab - RE3_PublishedData_DUO-O,DUO-O study
US - Durvalumab - RE3_PublishedData_DUO-O,What is the Study deisgn of DUO-O
US - Acalabrutinib - SA4_AEManagement_Heme_Bleeding,acalabrutinib and management of bleeding events
US - Acalabrutinib - SA4_AEManagement_Heme_Bleeding,management of hemorrhage in acalabrutinib trials
US - Acalabrutinib - SA4_AEManagement_Heme_Bleeding,calquence patients and management of bleeding
US - Acalabrutinib - SA4_AEManagement_Heme_Bleeding,Are there any recommendations on the management of bleedingin Calquence
US - Acalabrutinib - SA4_AEManagement_Heme_Bleeding,management of bleeding and calquence
US - Durvalumab - RE4_OngoingStudies_POSEIDON_Safety,Summarizes POSEIDON safety results
US - Durvalumab - RE4_OngoingStudies_POSEIDON_Safety,imfinzi poseidon safety
US - Osimertinib - RE4_PublishedData_ADAURA_Safety,Safety outcomes in ADAURA
US - Osimertinib - RE4_PublishedData_ADAURA_Safety,adverse events/AE/AR in resectable NSCLC/adjuvant setting
US - Osimertinib - RE4_PublishedData_ADAURA_Safety,long-term tolerability ADAURA
US - Osimertinib - RE4_PublishedData_ADAURA_Safety,updated adaura safety results
US - Osimertinib - TE3_PreDrugUse_PlasmaTesting,Tagrisso HRD testing
US - Osimertinib - TE3_PreDrugUse_PlasmaTesting,Should I use plasma or tissue testing?
US - Osimertinib - TE3_PreDrugUse_PlasmaTesting,ctDNA in metastatic NSCLC
US - Osimertinib - TE3_PreDrugUse_PlasmaTesting,plasma testing
US - Osimertinib - TE3_PreDrugUse_PlasmaTesting,Tagrisso tissue testing 
US - Tremelimumab - SA3_AdverseEvents_Immune,IMAE incidence with treme and durva combination
US - Tremelimumab - SA3_AdverseEvents_Immune,What were imAEs in the Himalaya trial
US - Tremelimumab - SA3_AdverseEvents_Immune,What were imAEs in the Poseidon trial
US - Tremelimumab - SA3_AdverseEvents_Immune,imAE incidence with treme or treme+durva
US - Durvalumab - SA1_Safety,What are the side effects of IMFINZI?
US - Durvalumab - SA1_Safety,imfinzi side effect
US - Durvalumab - SA1_Safety,imfinzi adverse event
US - Durvalumab - SA1_Safety,imfinzi ae
US - Durvalumab - SA1_Safety,safety of durva treme metastatic NSCLC
US - Durvalumab - SA1_Safety,safety of durva treme mnsclc
US - Durvalumab - SA1_Safety,safety durva treme mnsclc
US - Durvalumab - SA1_Safety,safety durva treme metastatic nsclc
US - Olaparib - IN3_Reproduction_Pregnancy,Is Lynparza indicated in pregnant patients?
US - Olaparib - IN3_Reproduction_Pregnancy,Lynparza during pregnancy
US - Olaparib - IN3_Reproduction_Pregnancy,Use of Lynparza during pregnancy
US - Olaparib - IN3_Reproduction_Pregnancy,Lynparza and pregnancy
US - Olaparib - IN3_Reproduction_Pregnancy,Is Olaparib indicated in pregnant patients?
US - Olaparib - IN3_Reproduction_Pregnancy,Olaparib during pregnancy
US - Olaparib - IN3_Reproduction_Pregnancy,Use of Olaparib during pregnancy
US - Olaparib - IN3_Reproduction_Pregnancy,Olaparib and pregnancy
US - Durvalumab - DO2_Variations,Dosage modifications for Imfinzi® (durvalumab) due to adverse reactions
US - Durvalumab - DO2_Variations,imfinzi dose modifications
US - Durvalumab - DO2_Variations,imfinzi dose mod
US - Durvalumab - DO2_Variations,dose modification for durvalumab in case of adverse events
US - Olaparib - AD3_Route_PEGTube,Can Lynparza tablets be made into a suspension for patients who have difficulty swallowing?
US - Olaparib - AD3_Route_PEGTube,Can Lynparza tablets be split?
US - Olaparib - AD3_Route_PEGTube,Oral suspension lynparza
US - Olaparib - AD3_Route_PEGTube,Oral solution lynparza
US - Olaparib - AD3_Route_PEGTube,Can Lynparza tablets be administered via feeding tube?
US - Olaparib - AD3_Route_PEGTube,Can Lynparza tablets be administered via PEG tube?
US - Olaparib - AD3_Route_PEGTube,Lynparza/olaparib PEG tube feeding
US - Olaparib - AD3_Route_PEGTube,Lynparza/olaparib J-tube feeding
US - Olaparib - AD3_Route_PEGTube,Crushing Lynparza/olaparb tablets
US - Olaparib - AD3_Route_PEGTube,Dissolving Lynparza/olaparib tablets
US - Olaparib - AD3_Route_PEGTube,Splitting Lynparza/olaparib tablets
US - Olaparib - AD3_Route_PEGTube,Crushing Lynparza/olaparib
US - Olaparib - AD3_Route_PEGTube,Splitting Lynparza/olaparib
US - Olaparib - AD3_Route_PEGTube,Dissolving Lynparza/olaparib
US - Olaparib - AD3_Route_PEGTube,Lynparza difficulty swallowing
US - Olaparib - AD3_Route_PEGTube,Lynparza in patients difficulty swallowing
US - Olaparib - AD3_Route_PEGTube,Lynparza adminstration in patients with difficulty swallowing
US - Olaparib - AD3_Route_PEGTube,NG-tube feeding Lynparza
US - Olaparib - AD3_Route_PEGTube,G-tube feeding Lynparza
US - Olaparib - RE3_PublishedData_MEDIOLA,Tell me about the MEDIOLA study
US - Olaparib - RE3_PublishedData_MEDIOLA,MEDIOLA
US - Olaparib - RE3_PublishedData_MEDIOLA,MEDIOLA study
US - Olaparib - RE3_PublishedData_MEDIOLA,Durvalumab and olaparib in ovarian cancer
US - Olaparib - RE3_PublishedData_MEDIOLA,Imfinzi and Lynparza in ovarian cancer
US - Olaparib - RE3_PublishedData_MEDIOLA,MEDIOLA study results
US - Olaparib - RE3_PublishedData_MEDIOLA,MEDIOLA results
US - Olaparib - RE3_PublishedData_MEDIOLA,Olaparib and durvalumab
US - Olaparib - RE3_PublishedData_MEDIOLA,Imfinzi and Lynparza
US - Olaparib - RE3_PublishedData_MEDIOLA,Lynparza and Imfinzi
US - Olaparib - RE3_PublishedData_MEDIOLA,Durvalumab and olaparib
US - Olaparib - RE3_PublishedData_MEDIOLA,Olaparib and durvalumab in ovarian cancer
US - Olaparib - RE3_PublishedData_MEDIOLA,Durvalumab and olaparib in ovarian cancer
US - Durvalumab - RE3_OngoingStudies_PAC5,Details on study design of PACIFIC 5
US - Durvalumab - RE3_OngoingStudies_PAC5, What were the results of the PAC5 study
US - Durvalumab - RE3_OngoingStudies_PAC5,imfinzi pac5
US - Durvalumab - RE3_OngoingStudies_PAC5,imfinzi pacific 5
US - Durvalumab - IN3_Immune_Autoimmune,Can you use Imfinzi® (durvalumab) in a patient with autoimmune disease?
US - Durvalumab - IN3_Immune_Autoimmune,imfinzi autoimmune
US - Capivasertib - CAPITELLO-291,What are the results for Capitello-291? 
US - Capivasertib - CAPITELLO-291,Capitello-291 trial design
US - Capivasertib - CAPITELLO-291,Capitello-291 results
US - Capivasertib - CAPITELLO-291,Capitello-291 study overview 
US - Osimertinib - CheckpointInhibitor_After,Can I use a checkpoint inhibitor after Osimertinib?
US - Osimertinib - CheckpointInhibitor_After,Can I use a checkpoint inhibitor after Tagrisso?
US - Osimertinib - CheckpointInhibitor_After,ICI/CPI as subsequent treatment; nivolumab/pembrolizumab/atezolimumab after progression on Tagrisso
US - Osimertinib - CheckpointInhibitor_After,ICI/CPI as subsequent treatment; nivolumab/pembrolizumab/atezolimumab after progression on osimertinib
US - Osimertinib - CheckpointInhibitor_After,IO after osimertinib
US - Osimertinib - CheckpointInhibitor_After,IO after Tagrisso
US - Acalabrutinib - IN3_Heme_WM,Acalabrutinib in Waldenström Macroglobulinemia (WM)
US - Acalabrutinib - IN3_Heme_WM,Calquence in WM
US - Acalabrutinib - IN3_Heme_WM,acalabrutinib in ACE-WM-001
US - Acalabrutinib - IN3_Heme_WM,Do you have information on the use of acalabrutinib in patients with Waldenström Macroglobulinemia (WM)?
US - Durvalumab - AV1_Availability,How do you order IMFINZI?
US - Olaparib - RE3_PUBLISHEDDATA_DUO-E,DUO-E study
US - Olaparib - RE3_PUBLISHEDDATA_DUO-E,DUO-E efficacy
US - Olaparib - RE3_PUBLISHEDDATA_DUO-E,Efficacy of DUO-E
US - Olaparib - RE3_PUBLISHEDDATA_DUO-E,Efficacy results DUO-E
US - Olaparib - RE3_PUBLISHEDDATA_DUO-E,Efficacy in DUO-E
US - Olaparib - RE3_PUBLISHEDDATA_DUO-E,Olaparib DUO-E study
US - Olaparib - RE3_PUBLISHEDDATA_DUO-E,Lynparza DUO-E study
US - Olaparib - RE3_PUBLISHEDDATA_DUO-E,Durvalumab DUO-E study
US - Olaparib - RE3_PUBLISHEDDATA_DUO-E,Imfinzi DUO-E study
US - Capivasertib - MECHANISM OF ACTION,What is the MOA of capivasertib?
US - Capivasertib - MECHANISM OF ACTION,MOA of capivasertib
US - Capivasertib - MECHANISM OF ACTION,mechanism of action of capivasertib
US - Capivasertib - MECHANISM OF ACTION,how does capivasertib work
US - Durvalumab - DE3_Structure_SpecificGravity,What is the specific gravity of Imfinzi® (durvalumab)?
US - Durvalumab - DE3_Structure_SpecificGravity,imfinzi specific gravity
US - Durvalumab - DE3_Structure_SpecificGravity,imfinzi sp grav
US - Acalabrutinib - CP2_MOA,What is the mechanism of action of Calquence?
US - Acalabrutinib - CP2_MOA,Acalabrutinib MOA
US - Acalabrutinib - CP2_MOA,Calquence MOA
US - Capivasertib - IN1_INDICATIONSCLINICALUSE,Capi approved indication
US - Capivasertib - IN1_INDICATIONSCLINICALUSE,Capivasertib approved indication
US - Capivasertib - IN1_INDICATIONSCLINICALUSE,TRUQAP approved indication
US - Capivasertib - IN1_INDICATIONSCLINICALUSE,Capivasertib with fulvestrant
US - Capivasertib - IN1_INDICATIONSCLINICALUSE,info about capivasertib with fulvestrant
US - Capivasertib - IN1_INDICATIONSCLINICALUSE,can I get details about capivasertib with fulvestrant
US - Capivasertib - IN1_INDICATIONSCLINICALUSE,I want to know about capivasertib with fulvestrant
US - Durvalumab - AD3_Error_Extravasation,Imfinzi® (durvalumab)-Reports of infiltration or extravasation
US - Durvalumab - AD3_Error_Extravasation,durvalumab extravasation
US - Camizestrant - DE1_Description,Tell me about camizestrant
US - Camizestrant - RE4_PublishedData_SERENA1_Safety,What is the safety profile of camizestrant in SERENA-1
US - Camizestrant - RE4_PublishedData_SERENA1_Safety,What are the most common AEs in SERENA-1
US - Acalabrutinib - CO1_Cost,What's the cost of Calquence?
US - Acalabrutinib - CO1_Cost,Acalabrutinib cost
US - Acalabrutinib - SA4_AdverseEvents_ID_Fungal,fungal infections with acalabrutinib
US - Acalabrutinib - SA4_AdverseEvents_ID_Fungal,aspergillosis with calquence
US - Acalabrutinib - SA4_AdverseEvents_ID_Fungal,mycotic infections with acalabrutinib
US - Acalabrutinib - SA4_AdverseEvents_ID_Fungal,candidiasis with calquence
US - Acalabrutinib - SA4_AdverseEvents_ID_Fungal,candida infection and acalabrutinib
US - Osimertinib - SA4_AdverseEvents_Respiratory_ILD,Pneumonitis / ILD
US - Osimertinib - SA4_AdverseEvents_Respiratory_ILD,ILD/pneumonitis in metastatic NSCLC
US - Acalabrutinib - IN3_Heme_CLL,Use of acalabrutinib in CLL?
US - Acalabrutinib - IN3_Heme_CLL,Calquence in treament naive CLL
US - Acalabrutinib - IN3_Heme_CLL,Calquence in relapsed/refractory CLL
US - Acalabrutinib - IN3_Heme_CLL,Acala/acalabrutinib/Calquence in TN CLL
US - Acalabrutinib - IN3_Heme_CLL,Acala/acalabrutinib/Calquence in RR CLL
US - Acalabrutinib - IN3_Heme_CLL,Can acalabrutinib be used for patients with CLL?
US - Olaparib - CO1_Cost,What's the cost of Lynparza?
US - Olaparib - CO1_Cost,Price of Lynparza
US - Olaparib - CO1_Cost,Lynparza price
US - Olaparib - CO1_Cost,Lynparza cost
US - Olaparib - CO1_Cost,What's the cost of Olaparib?
US - Olaparib - CO1_Cost,Price of Olaparib
US - Olaparib - CO1_Cost,Olaparib price
US - Olaparib - CO1_Cost,Olaparib cost
US - Acalabrutinib - SA4_AdverseEvents_Resp_Pneumonitis,interstitial lung disease with acalabrutinib
US - Acalabrutinib - SA4_AdverseEvents_Resp_Pneumonitis,pneumonitis and acalabrutinib
US - Acalabrutinib - SA4_AdverseEvents_Resp_Pneumonitis,ILD and calquence
US - Acalabrutinib - SA4_AdverseEvents_Resp_Pneumonitis,ILD and acalabrutinib
US - Acalabrutinib - SA4_AdverseEvents_Resp_Pneumonitis,pneumonitis with calquence
US - Acalabrutinib - SA4_AdverseEvents_Resp_Pneumonitis,What is the incidence of pneumonitis/interstitial lung disease (ILD) with acalabrutinib.?
US - Acalabrutinib - SA4_AdverseEvents_Resp_Pneumonitis,interstitial lung disease with calquence
US - Olaparib - SS4_ContactPharmaGroup_ESMOGynCongress_ESMOGYN 2023,ESMO GYN 2023 Lynparza
US - Osimertinib - IN2_Condition,Can I use Tagrisso in earlier disease stages?
US - Osimertinib - IN2_Condition,Can osi/ osimertinib be used for earier disease stages of NSCLC? 
US - Osimertinib - IN2_Condition,tagrisso in resectable NSCLC
US - Osimertinib - IN2_Condition,tagrisso resectable NSCLC
US - Osimertinib - IN3_PlaceInTherapy_SecondLineTherapy,What can I treat with when my patient with T790M progresses after second-line Osimertinib
US - Osimertinib - IN3_PlaceInTherapy_SecondLineTherapy,progression on second-line osimertinib
US - Osimertinib - IN3_PlaceInTherapy_SecondLineTherapy,Tagrisso T790M progression
US - Osimertinib - IN3_PlaceInTherapy_SecondLineTherapy,osimertinib after T790M progression
US - Olaparib - RE4_PublishedData_OlympiA_Safety,What are the safety results from the Olympia trial?
US - Olaparib - RE4_PublishedData_OlympiA_Safety,OlympiA safety results
US - Olaparib - RE4_PublishedData_OlympiA_Safety,OlympiA safety
US - Olaparib - RE4_PublishedData_OlympiA_Safety,Safety in OlympiA
US - Olaparib - RE4_PublishedData_OlympiA_Safety,Safety of OlympiA
US - Olaparib - ST3_ExtraordinaryCircumstances_Repackaged,Is there any stability data on Lynparza after it's removed from the original bottle and repackaged?
US - Olaparib - ST3_ExtraordinaryCircumstances_Repackaged,Can Lynparza/olaparib be stored in prescription bottle?
US - Olaparib - ST3_ExtraordinaryCircumstances_Repackaged,Lynparza/olaparib stored in prescription bottleG
US - Olaparib - ST3_ExtraordinaryCircumstances_Repackaged,Lynparza/olaparib repackaging
US - Osimertinib - DO3_Variations_LeptomeningealMets,Is 160 mg better than 80 mg for LM?
US - Osimertinib - DO3_Variations_LeptomeningealMets,osimertinib dose for leptomeningeal disease
US - Osimertinib - DO3_Variations_LeptomeningealMets,leptomeningeal dose 
US - Camizestrant - RE3_PublishedData_SERENA4,What is the trial design for SERENA-4? m
US - T-dxd - RE3_OngoingStudies_Gastric,ENHERTU Ongoing gastric trials
US - Acalabrutinib - IN3_Subgroup_Geriatrics,Is Calquence indicated in geriatrics patients?
US - Acalabrutinib - IN3_Subgroup_Geriatrics,Calquence in geriatric patients
US - Acalabrutinib - IN3_Subgroup_Geriatrics,Calquence in elderly patients
US - Acalabrutinib - IN3_Subgroup_Geriatrics,Acalabrutinib in Old patients
US - Osimertinib - RE4_OngoingStudies_AURA3_Safety,AURA3 safety
US - Osimertinib - RE4_OngoingStudies_AURA3_Safety,AURA3 Study safety
US - Osimertinib - RE4_OngoingStudies_AURA3_Safety,AURA3 Trial safety
US - Osimertinib - RE4_OngoingStudies_AURA3_Safety,AURA 3 Trial/Study safety
US - Osimertinib - RE4_OngoingStudies_AURA3_Safety,AURA 3 safety
US - Olaparib - RE3_PublishedData_OreO,Can you provide information on the OREO study?
US - Olaparib - RE3_PublishedData_OreO,Can you provide information on the re-treatment with olaparib in ovarian cancer?
US - Olaparib - RE3_PublishedData_OreO,Can you provide information on the OREO presentation at ESMO or other congresses?
US - Olaparib - RE3_PublishedData_OreO,OReO study results
US - Olaparib - RE3_PublishedData_OreO,OReO results
US - Olaparib - RE3_PublishedData_OreO,OReO data
US - Osimertinib - AV1_Availability,How can I order osimertinib?
US - Osimertinib - AV1_Availability,distributor; distribution
US - Osimertinib - AV1_Availability,What is the availability of TAGRISSO?
US - T-DXd - CO3_Support_FinancialAssistance,Is there financial support for Enhertu
US - Durvalumab - RE4_PublishedData_MEDIOLA_Safety,Safety of MEDIOLA
US - Durvalumab - RE4_PublishedData_MEDIOLA_Safety,Safety of Imfinzi and Lynparza in ovarian cancer
US - Durvalumab - RE4_PublishedData_MEDIOLA_Safety,MEDIOLA Safety
US - Durvalumab - RE4_PublishedData_MEDIOLA_Safety,Safety of durvalumab and olaparib in ovarian cancer
US - Durvalumab - RE4_PublishedData_MEDIOLA_Safety,MEDIOLA safety results
US - Durvalumab - RE4_PublishedData_MEDIOLA_Safety,Safety of Imfinzi and Lynparza
US - Durvalumab - RE4_PublishedData_MEDIOLA_Safety,Safety of Lynparza and Imfinzi ovarian cancer
US - Durvalumab - IN3_Resp_NSCLC,Trials in NSCLC
US - Durvalumab - IN3_Resp_NSCLC,imfinzi nsclc
US - Olaparib - DI3_Food_Grapefruit,Can Lynparza be administered with grapefruit or Seville oranges?
US - Olaparib - DI3_Food_Grapefruit,Lynparza/olaparib with grapefruit
US - Olaparib - DI3_Food_Grapefruit,Lynparza/olaparib with grapefruit or seville oranges
US - Olaparib - DI3_Food_Grapefruit,Drinking grapefruit juice with lynparza/olaparib
US - Olaparib - DI3_Food_Grapefruit,Eating grapefruit with Lynparza/olaparib
US - Olaparib - DI3_Food_Grapefruit,Eating Seville oranges with Lyparza/olaparib
US - Durvalumab - RE3_OngoingStudies_PAC6,Details on study design of PACIFIC 6
US - Durvalumab - RE3_OngoingStudies_PAC6,Purpose of the PAC6 study
US - Durvalumab - RE3_OngoingStudies_PAC6,imfinzi pac6
US - Durvalumab - RE3_OngoingStudies_PAC6,imfinzi pacific 6
US - Olaparib - IN1_IndicationsClinicalUse,What is Lynparza indicated for?
US - Olaparib - IN1_IndicationsClinicalUse,Lynparza/olaparib indications
US - Olaparib - IN1_IndicationsClinicalUse,Lynparza/olaparib clinical indications
US - Olaparib - IN1_IndicationsClinicalUse,Lynparza clinical studies
US - Olaparib - IN1_IndicationsClinicalUse,Lynparza studies
US - Olaparib - IN1_IndicationsClinicalUse,Lynparza clinical trials first-line maintenance
US - Olaparib - IN1_IndicationsClinicalUse,Lynparza clinical trials ovarian cancer
US - Olaparib - IN1_IndicationsClinicalUse,PROpel PI
US - Olaparib - IN1_IndicationsClinicalUse,PROpel Prescibing information
US - Olaparib - IN1_IndicationsClinicalUse,PROpel indication
US - Olaparib - IN1_IndicationsClinicalUse,PROpel approval
US - Durvalumab - RE4_OngoingStudies_POSEIDON_Biomarkers,Biomarker subgroup analysis imfinzi
US - Durvalumab - RE4_OngoingStudies_POSEIDON_Biomarkers,imfinzi Biomarker subgroup analysis
US - Durvalumab - RE4_OngoingStudies_POSEIDON_Biomarkers,Imfinzi STK11m
US - Durvalumab - RE4_OngoingStudies_POSEIDON_Biomarkers,Imfinzi KRAS
US - Durvalumab - RE4_OngoingStudies_POSEIDON_Biomarkers,Imfinzi KRASm
US - Durvalumab - RE4_OngoingStudies_POSEIDON_Biomarkers,Imfinzi KEAP1
US - Durvalumab - RE4_OngoingStudies_POSEIDON_Biomarkers,Imfinzi KEAP1m
US - Durvalumab - RE4_OngoingStudies_POSEIDON_Biomarkers,Imfinzi STK11
US - Durvalumab - IN3_Hepatic_HCC,Use in HCC (hepatocellular carcinoma)
US - Durvalumab - IN3_Hepatic_HCC,Imfinzi data in HCC patients
US - Durvalumab - IN3_Hepatic_HCC,Imfinzi HCC trials
US - T-dxd - RE3_PublishedData_DESTINYLung,Enhertu NSCLC
US - T-dxd - RE3_PublishedData_DESTINYLung,Enhertu lung cancer
US - T-dxd - RE3_PublishedData_DESTINYLung,Enhertu lung
US - T-dxd - RE3_PublishedData_DESTINYLung,T-DXd NSCLC
US - T-dxd - RE3_PublishedData_DESTINYLung,T-DXd lung cancer
US - T-dxd - RE3_PublishedData_DESTINYLung,T-DXd lung
US - T-dxd - RE3_PublishedData_DESTINYLung,Destiny lung cancer
US - Olaparib - ESMO BREAST CONGRESS 2023,ESMO Breast 23 Lynparza
US - Olaparib - ESMO BREAST CONGRESS 2023,ESMOBC 23 congress Lynparza
US - Olaparib - ESMO BREAST CONGRESS 2023,ESMO BC 2023 information Lynparza
US - Olaparib - ESMO BREAST CONGRESS 2023,Lynparza ESMO-BC 23
US - Olaparib - ESMO BREAST CONGRESS 2023,2023 ESMO BC Lynparza
US - Olaparib - ESMO BREAST CONGRESS 2023,ESMOBreast23 poster Lynparza
US - Olaparib - ESMO BREAST CONGRESS 2023,posters from ESMO Breast 2023 Lynparza
US - Olaparib - TE3_PreDrugUse_TissueTesting,Do you have any data on concordance between tumor tissue testing and plasma ctDNA testing? Lynparza
US - Olaparib - TE3_PreDrugUse_TissueTesting,Concordance between tumor tissue testing and plasma ctDNA testing Lynparza
US - Olaparib - TE3_PreDrugUse_TissueTesting,mCRPC tissue testing Lynparza
US - Olaparib - TE3_PreDrugUse_TissueTesting,concordance data prostate cancer Lynparza
US - Olaparib - IN3_Reproduction_Lactation,Is Lynparza indicated in lactating patients?  
US - Olaparib - IN3_Reproduction_Lactation,Is Lynparza secreted in breast milk?
US - Olaparib - IN3_Reproduction_Lactation,Is Lynparza indicated for use during breastfeeding?  
US - Olaparib - IN3_Reproduction_Lactation,Lynparza and breastfeeding
US - Olaparib - IN3_Reproduction_Lactation,Breastfeeding during Lynparza
US - Olaparib - IN3_Reproduction_Lactation,Is Olaparib indicated in lactating patients?  
US - Olaparib - IN3_Reproduction_Lactation,Is Olaparib secreted in breast milk?
US - Olaparib - IN3_Reproduction_Lactation,Is Olaparib indicated for use during breastfeeding?  
US - Olaparib - IN3_Reproduction_Lactation,Olaparib and breastfeeding
US - Olaparib - IN3_Reproduction_Lactation,Breastfeeding during Olaparib
US - Olaparib - RE4_PublishedData_PROfound_TissueTesting,What is the tissue testing success rate in Profound?
US - Olaparib - RE4_PublishedData_PROfound_TissueTesting,tissue testing success in prostate lynparza
US - Olaparib - RE4_PublishedData_PROfound_TissueTesting,What is the tissue testing success rate in PROpel?
US - Olaparib - RE4_PublishedData_PROfound_TissueTesting,success rate in tissue testing for profound
US - Olaparib - RE4_PublishedData_PROfound_TissueTesting,success rate in tissue testing for PROpel
US - T-dxd - RE3_PublishedData_DESTINYCRC01,What are the results of DESTINY-CRC01?
US - T-dxd - RE3_PublishedData_DESTINYCRC01,ENHERTU CRC01
US - Camizestrant - RE3_PublishedData_SERENA6,What is the trial design for SERENA-6? 
US - Acalabrutinib - SA4_AdverseEvents_ID_HepBReactivation,Hepatitis B Virus Reactivation with acalabrutinib
US - Acalabrutinib - SA4_AdverseEvents_ID_HepBReactivation,HBV reactivation and calquence
US - Acalabrutinib - SA4_AdverseEvents_ID_HepBReactivation,Hep B and calquence
US - Acalabrutinib - SA4_AdverseEvents_ID_HepBReactivation,Is there any data on the occurrence of Hepatitis B Virus Reactivation with acalabrutinib?
US - Osimertinib - SS3_CONTACTPHARMAGROUP_WCLC2023,Tagrisso WCLC 2023
US - Osimertinib - SS3_CONTACTPHARMAGROUP_WCLC2023,Osimertinib WCLC 2023
US - Osimertinib - SS3_CONTACTPHARMAGROUP_WCLC2023,Tagrisso data from WCLC 2023
US - Osimertinib - SS3_CONTACTPHARMAGROUP_WCLC2023,Osimertinib data from WCLC 2023
US - Osimertinib - SS3_CONTACTPHARMAGROUP_WCLC2023,Savolitinib WCLC 2023
US - Osimertinib - SS3_CONTACTPHARMAGROUP_WCLC2023,Savolitinib data from WCLC 2023
US - Osimertinib - SS3_CONTACTPHARMAGROUP_WCLC2023,FLAURA2 WCLC 2023
US - Osimertinib - SS3_CONTACTPHARMAGROUP_WCLC2023,KCSG-LU15-09 WCLC 2023
US - Osimertinib - SS3_CONTACTPHARMAGROUP_WCLC2023,tagrisso WCLC/IASLC
US - Osimertinib - SS3_CONTACTPHARMAGROUP_WCLC2023,tagrisso data from WCLC
US - Osimertinib - SS3_CONTACTPHARMAGROUP_WCLC2023,tagrisso data from IASLC
US - Olaparib - SS3_ContactPharmaGroup_SGO2023,olaparib SGO 2023
US - Olaparib - SS3_ContactPharmaGroup_SGO2023,Lynparza SGO 2023
US - Olaparib - SS3_ContactPharmaGroup_SGO2023,May I see the OPUSR trial poster 
US - Olaparib - SS3_ContactPharmaGroup_SGO2023,Fetch me the info on OPUSR
US - Olaparib - SS3_ContactPharmaGroup_SGO2023,Lynparza Society of Gynecologic Oncology 2023
US - Olaparib - SS3_ContactPharmaGroup_SGO2023,Lynparza OPUS
US - Olaparib - SS3_ContactPharmaGroup_SGO2023,Lynparza Monaco
US - Osimertinib - IN3_PlaceInTherapy_CheckpointInhibitors,Can I use Tagrisso® (osimertinib) with checkpoint inhibitors?
US - Osimertinib - IN3_PlaceInTherapy_CheckpointInhibitors,Can I use Osimertinib after a checkpoint inhibitor?
US - Osimertinib - IN3_PlaceInTherapy_CheckpointInhibitors,Can I use a checkpoint inhibitor after Osimertinib?
US - Olaparib - RE4_PublishedData_SOLO1_Safety,What is the safety of SOLO-1?       
US - Olaparib - RE4_PublishedData_SOLO1_Safety,SOLO-1 safety
US - Olaparib - RE4_PublishedData_SOLO1_Safety,SOLO-1 safety data
US - Olaparib - RE4_PublishedData_SOLO1_Safety,SOLO-1 safety results
US - Olaparib - RE4_PublishedData_SOLO1_Safety,SOLO-1 long-term safety
US - Olaparib - RE4_PublishedData_SOLO1_Safety,SOLO-1 7-year safety
US - Olaparib - RE4_PublishedData_SOLO1_Safety,SOLO-1 7-year data
US - Olaparib - RE4_PublishedData_SOLO1_Safety,SOLO-1 updated safety
US - Olaparib - RE4_PublishedData_SOLO1_Safety, SOLO-1 updated safety results
US - Olaparib - RE4_PublishedData_SOLO1_Safety,SOLO-1 long term safety results
US - Olaparib - RE4_PublishedData_SOLO1_Safety,SOLO-1 long-term safety data
US - Durvalumab - RE3_OngoingStudies_HUDSON,HUDSON Trial
US - Durvalumab - RE3_OngoingStudies_HUDSON,imfinzi hudson
US - Durvalumab - RE3_OngoingStudies_HUDSON,Imfinzi and Enhertu in lung cancer
US - Durvalumab - RE3_OngoingStudies_HUDSON,Imfinzi and Enhertu in NSCLC
US - Durvalumab - RE3_OngoingStudies_HUDSON,durvalumab and trastuzumab deruxtecan in lung cancer
US - Durvalumab - RE3_OngoingStudies_HUDSON,durvalumab and trastuzumab deruxtecan in NSCLC 
US - Durvalumab - RE3_OngoingStudies_HUDSON,durvalumab and T-DXd in lung cancer 
US - Durvalumab - RE3_OngoingStudies_HUDSON,durvalumab and T-DXd in NSCLC
US - Camizestrant - SS3_CONTACTPHARMAGROUP_SABCS2023,camizestrant SABCS 2023
US - Camizestrant - SS3_CONTACTPHARMAGROUP_SABCS2023,SABCS Breast camizestrant 2023
US - Camizestrant - SS3_CONTACTPHARMAGROUP_SABCS2023,CAMBRIA-1 SABCS 2023
US - Camizestrant - SS3_CONTACTPHARMAGROUP_SABCS2023,CAMBRIA-2 SABCS 2023
US - Camizestrant - SS3_CONTACTPHARMAGROUP_SABCS2023,CAMBRIA SABCS 2023
US - Osimertinib - EF2_ClinicalTrials,What data do you have for Tagrisso
US - Osimertinib - EF2_ClinicalTrials,Clinical trials on Tagrisso
US - Osimertinib - EF2_ClinicalTrials,Clinical trials/ efficacy data for osimertinib
US - Osimertinib - EF2_ClinicalTrials,What is the efficacy of Tagrisso?
US - Osimertinib - EF2_ClinicalTrials,tagrisso efficacy
US - Osimertinib - EF2_ClinicalTrials,tagrisso efficiency
US - Osimertinib - EF2_ClinicalTrials,tagrisso efficacy results
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_BRCA,What is the data for patients with prostate cancer with a BRCA gene mutation? Lynparza
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_BRCA,Prostate BRCA lynparza
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_BRCA,PROfound BRCA lynparza
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_BRCA,BRCA data in prostate lynparza
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_BRCA,Prostate trials with BRCA mutation
US - Dato-dxd - RE4_PublishedData_PanTumor01_Lung,What are the preliminary results in advanced/metastatic NSCLC cohort in the TROPION - PanTumor01 study?
US - Tremelimumab - AD3_Instructions_Reconstitution,Types of infusion bags used in Treme
US - Tremelimumab - AD3_Instructions_Reconstitution,In-line filter in Treme
US - Tremelimumab - AD3_Instructions_Reconstitution,Storage of reconstituted product for Treme
US - Tremelimumab - AD3_Instructions_Reconstitution,Temp excursion of reconstituted product in Treme
US - Tremelimumab - AD3_Instructions_Reconstitution,Preparation of Trem
US - Tremelimumab - AD3_Instructions_Reconstitution,Administration of treme
US - Tremelimumab - AD3_Instructions_Reconstitution,treme recon
US - Tremelimumab - AD3_Instructions_Reconstitution,treme reconstitution 
US - Osimertinib - RE3_OngoingStudies_AURA3,AURA3
US - Osimertinib - RE3_OngoingStudies_AURA3,AURA3 Study
US - Osimertinib - RE3_OngoingStudies_AURA3,AURA3 Trial
US - Olaparib - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2023,ASCO 2023 Lynparza
US - Olaparib - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2023,ASCO23 Lynparza
US - Olaparib - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2023,Information on ASCO 2023 Lynparza
US - Olaparib - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2023,ASCO Breast 2023 Lynparza
US - Olaparib - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2023,ASCO BC 23 Lynparza
US - Olaparib - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2023,ASCO23 Poster Lynparza
US - Olaparib - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2023,Poster from ASCO 23 Lynparza
US - Olaparib - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2023,2023 ASCO Lynparza
US - Olaparib - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2023,23 ASCO BC Lynparza
US - Olaparib - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2023,VIOLETTE ASCO 23 Lynparza
US - Olaparib - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2023,ASCO 2023 Olaparib
US - Olaparib - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2023,ASCO23 Olaparib
US - Olaparib - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2023,Information on ASCO 2023 Olaparib
US - Olaparib - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2023,ASCO Breast 2023 Olaparib
US - Olaparib - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2023,ASCO BC 23 Olaparib
US - Olaparib - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2023,ASCO23 Poster Olaparib
US - Olaparib - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2023,Poster from ASCO 23 Olaparib
US - Olaparib - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2023,2023 ASCO Olaparib
US - Olaparib - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2023,23 ASCO BC Olaparib
US - Olaparib - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2023,VIOLETTE ASCO 23 Olaparib
US - Durvalumab - EF3_ClinicalTrials_PDL1,Does PD-L1 level affect the efficacy of Imfinzi® (durvalumab) in the unresectable stage III setting?
US - Durvalumab - EF3_ClinicalTrials_PDL1,imfinzi stage iii pdl1
US - T-DXd - DO4_Variations_Resp_ILD,Dose modifications for ILD/pneumonitis
US - T-DXd - DO4_Variations_Resp_ILD,Enhertu ILD/pneumonitis management
US - Durvalumab - AD1_Administration,How do you administer Imfinzi® (durvalumab)?
US - Durvalumab - AD1_Administration,what is administration of imfinzi
US - Durvalumab - AD1_Administration,imfinzi administration
US - Durvalumab - AD1_Administration,imfinzi admin
US - Olaparib - RE4_PublishedData_PROpel_MOA,Mechanism of action (MoA) for olaparib and abiraterone combination therapy in PROpel study?
US - Olaparib - RE4_PublishedData_PROpel_MOA,olaparib and abiraterone MoA
US - Olaparib - RE4_PublishedData_PROpel_MOA,olaparib and abiraterone combination action
US - Olaparib - RE4_PublishedData_PROpel_MOA,olaparib+abiraterone MoA
US - Olaparib - RE4_PublishedData_PROpel_MOA,olaparib+abiraterone combination action
US - Olaparib - RE4_PublishedData_PROpel_MOA,PROpel MoA
US - Olaparib - RE4_PublishedData_PROpel_MOA,PROpel mechanism of action
US - Olaparib - RE4_PublishedData_PROpel_MOA,Study 8 MoA
US - Olaparib - RE4_PublishedData_PROpel_MOA,study 8 mechanism of action
US - Olaparib - RE4_PublishedData_PROpel_MOA,PROpel MoA video
US - Durvalumab - RE3_PublishedData_HIMALAYA,What are the results of the HIMALAYA trial?
US - Durvalumab - RE3_PublishedData_HIMALAYA,Data from Himalaya
US - Durvalumab - RE3_PublishedData_HIMALAYA,Himalaya trial information
US - Durvalumab - RE3_PublishedData_HIMALAYA,Updated OS for the HIMALAYA trial
US - Durvalumab - RE3_PublishedData_HIMALAYA,Overall survival for the HIMALAYA trial
US - Durvalumab - RE3_PublishedData_HIMALAYA,Overall efficacy data for the HIMALAYA trial
US - Durvalumab - RE3_PublishedData_HIMALAYA,Exploratory data from the HIMALAYA trialconversation 
US - Durvalumab - RE3_PublishedData_HIMALAYA,Updated results from the HIMALAYA trial
US - T-DXd - EF1_Efficacy,What is the efficacy of Enhertu?
US - T-DXd - EF1_Efficacy,Efficacy results of enhertu
US - T-DXd - EF1_Efficacy,Efficacy data for enhertu
US - T-DXd - EF1_Efficacy,Efficacy data for enhertu low
US - T-DXd - EF1_Efficacy,Efficacy data enhertu her 2 low
US - T-DXd SS3_ContactPharmaGroup_Congress,Congress materials Enhertu
US - Osimertinib - AD3_Instructions_Split,Can I split the tablet?
US - Osimertinib - AD3_Instructions_Split,Can I cut the tablet?
US - Osimertinib - AD3_Instructions_Split,Can I crush the tablet?
US - Osimertinib - AD3_Instructions_Split,half; halve
US - Osimertinib - AD3_Instructions_Split,crush; crushed
US - Osimertinib - AD3_Instructions_Split,Can tagrisso be a liquid?
US - Osimertinib - AD3_Instructions_Split,tagrisso liquid
US - Osimertinib - AD3_Instructions_Split,Rectal administration tagrisso
US - Osimertinib - AD3_Instructions_Split,Has osimertinib been studied as rectal administration
US - Durvalumab - RE2_OngoingStudies,General response about ongoing trials Imfinzi
US - Durvalumab - RE2_OngoingStudies,Ongoing clinical trials
US - Osimertinib - SA3_AdverseEvents_Heme,Aplastic anemia with Tagrisso
US - Osimertinib - SA3_AdverseEvents_Heme,Anemia with Tagrisso
US - Osimertinib - SA3_AdverseEvents_Heme,Blood count decrease with Tagrisso
US - Osimertinib - SA3_AdverseEvents_Heme,Blood disorder with Tagrisso
US - T-DXd - SS4_HCPSupport_Resources_PrescribingInformation,Enhertu PI
US - Durvalumab - IN3_Procedures_Surgery,Can you use Imfinzi® (durvalumab) in patients undergoing surgery?
US - Durvalumab - IN3_Procedures_Surgery,imfinzi surgery
US - T-DXd - DO1_Dosing,What is the dose of Enhertu?
US - Durvalumab - DO3_LateDose_MissedDose,What happens if the patient misses an Imfinzi® (durvalumab) dose or there is a dosing delay?
US - Durvalumab - DO3_LateDose_MissedDose,imfinzi missed dose
US - Olaparib - RE4_PublishedData_MEDIOLA_Safety,Safety of MEDIOLA
US - Olaparib - RE4_PublishedData_MEDIOLA_Safety,Safety of Imfinzi and Lynparza in ovarian cancer
US - Olaparib - RE4_PublishedData_MEDIOLA_Safety,MEDIOLA Safety
US - Olaparib - RE4_PublishedData_MEDIOLA_Safety,Safety of durvalumab and olaparib in ovarian cancer
US - Olaparib - RE4_PublishedData_MEDIOLA_Safety,MEDIOLA safety results
US - Olaparib - RE4_PublishedData_MEDIOLA_Safety,Safety of Imfinzi and Lynparza
US - Olaparib - RE4_PublishedData_MEDIOLA_Safety,Safety of Lynparza and Imfinzi ovarian cancer
US - Osimertinib - AD3_Coadministration_CYP3AInducers,Administration with a CYP3A4 inducer
US - Osimertinib - AD3_Coadministration_CYP3AInducers,CYP3A
US - Osimertinib - AD3_Coadministration_CYP3AInducers,CYP inducer
US - Osimertinib - AD3_Coadministration_CYP3AInducers,tagrisso and CYP inducer
US - Osimertinib - AD3_Coadministration_CYP3AInducers,Osimertinib and CYP inducer
US - Osimertinib - AD3_Coadministration_CYP3AInducers,Osi and CYP inducer
US - Osimertinib - CO1_Cost,What's the cost of Tagrisso® (osimertinib)?
US - Osimertinib - CO1_Cost,cost
US - Osimertinib - CO1_Cost,price
US - Durvalumab - EF2_ClinicalTrials,Trial data Imfinzi
US - Durvalumab - EF2_ClinicalTrials,clinical data Imfinzi
US - Durvalumab - EF2_ClinicalTrials,product efficacy Imfinzi
US - Osimertinib - EF3_ClinicalTrials_Chemotherapy,Did chemotherapy affect ADAURA outcomes?
US - Osimertinib - EF3_ClinicalTrials_Chemotherapy,chemotherapy regimens in ADAURA/adjuvant setting
US - Osimertinib - EF3_ClinicalTrials_Chemotherapy,chemotherapy in early stage
US - Osimertinib -RE3_OngoingStudies_ORCHARD,ORCHARD trial
US - Osimertinib -RE3_OngoingStudies_ORCHARD,ORCHARD study
US - Osimertinib -RE3_OngoingStudies_ORCHARD,ORCHARD
US - Osimertinib - CO3_Support_Program,Is there a patient support program for Tagrisso® (osimertinib)?
US - Olaparib - CO3_Support_FinancialAssistance,Is there financial assistance for Lynparza?
US - Olaparib - CO3_Support_FinancialAssistance,Is there financial assistance for olaparib?
US - Olaparib - CO3_Support_FinancialAssistance,Financial assistance for Lynparza/olaparib
US - Olaparib - SA4_AdverseEvents_Reproduction_Prostate,What are the adverse events in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving Lynparza® (olaparib)?
US - Olaparib - SA4_AdverseEvents_Reproduction_Prostate, What is the median time to onset or median duration of first event of AEs for prostate cancer patients on olaparib treatment?.
US - Olaparib - SA4_AdverseEvents_Reproduction_Prostate,olaparib safety prostate
US - Olaparib - SA4_AdverseEvents_Reproduction_Prostate,olaparib safety mCRPC
US - Olaparib - SA4_AdverseEvents_Reproduction_Prostate,AE prostate lynparza
US - Olaparib - SA4_AdverseEvents_Reproduction_Prostate,Prostate AE lynparza
US - Osimertinib - IN2_Renal,Can I use Tagrisso in patients with renal impairment?
US - Osimertinib - IN2_Renal,Kidney impairment
US - Osimertinib - IN2_Renal,Renal disease tagrisso
US - Osimertinib - IN2_Renal,renal impairment tagrisso
US - Osimertinib - IN2_Renal,kidney disease
US - Durvalumab - RE4_PublishedData_PACIFICR_ESMO,PACIFIC-R ESMO presentation
US - Durvalumab - IN3_Reproduction_Pregnancy,Can Imfinzi be used in pregnant patients?
US - Durvalumab - IN3_Reproduction_Pregnancy,imfinzi pregnancy
US - Durvalumab - IN3_Reproduction_Pregnancy,imfinzi pregnant
US - Durvalumab - IN3_Reproduction_Pregnancy,IMFINZI effects in pregnant women
US - Durvalumab - IN3_Reproduction_Pregnancy,effects of durvalumab in pregnant women
US - Durvalumab - IN3_Reproduction_Pregnancy,can I use imfinzi if pregnant
US - Durvalumab - RE3_PublishedData_PACIFIC,Are there studies for unresectable Stage III NSCLC patients Imfinzi
US - Durvalumab - RE3_PublishedData_PACIFIC,imfinzi pacific
US - Durvalumab - RE3_PublishedData_PACIFIC,Pacific OS
US - Durvalumab - RE3_PublishedData_PACIFIC,What is the overall survival for Imfinzi® (durvalumab) in the PACIFIC trial?
US - Durvalumab - RE3_PublishedData_PACIFIC,imfinzi pacific os
US - Durvalumab - RE3_PublishedData_PACIFIC,What were the efficacy outcomes from PACIFIC?
US - Durvalumab - RE3_PublishedData_PACIFIC,imfinzi pacific efficacy
US - Durvalumab - RE3_PublishedData_PACIFIC,PACIFIC 5-year OS
US - Durvalumab - RE3_PublishedData_PACIFIC,imfinzi pacific 5 year
US - Acalabrutinib - IN3_Reproduction_Lactation,Is Calquence indicated in lactating patients?
US - Acalabrutinib - IN3_Reproduction_Lactation,Calquence in nursing patients
US - Acalabrutinib - IN3_Reproduction_Lactation,Calquence in breastfeeding patients
US - Acalabrutinib - IN3_Reproduction_Lactation,Calquence in lactating patients
US - Olaparib - SA4_AdverseEvents_Heme_PulmonaryEmbolism,What is the rate of incidence of pulmonary embolism events in treatment with Lynparza?
US - Olaparib - SA4_AdverseEvents_Heme_PulmonaryEmbolism,Lynparza pulmonary embolism
US - Olaparib - SA4_AdverseEvents_Heme_PulmonaryEmbolism,Pulmonary embolism with Lynparza
US - Olaparib - SA4_AdverseEvents_Heme_PulmonaryEmbolism,Lynparza PE
US - Olaparib - SA4_AdverseEvents_Heme_PulmonaryEmbolism,Lynparza venous thromboembolic events
US - Olaparib - SA4_AdverseEvents_Heme_PulmonaryEmbolism,Lynparza VTE
US - Olaparib - SA4_AdverseEvents_Heme_PulmonaryEmbolism,PROpel PE
US - Olaparib - SA4_AdverseEvents_Heme_PulmonaryEmbolism,PROpel VTE
US - Osimertinib - ST2_OutOfSafeTempRange,There was a temperature excursion- is the supply still ok?
US - Osimertinib - ST2_OutOfSafeTempRange,tagrisso and temperature
US - Durvalumab - RE4_OngoingStudies_TOPAZ1_Efficacy,What were the efficacy outcomes from TOPAZ
US - Durvalumab - RE4_OngoingStudies_TOPAZ1_Efficacy,Topaz-1 efficacy results
US - Durvalumab - RE4_OngoingStudies_TOPAZ1_Efficacy,Topaz-1 OS data
US - Durvalumab - RE4_OngoingStudies_TOPAZ1_Efficacy,What were the efficacy results for TOPAZ-1
US - Durvalumab - AD4_Route_IV_InLineFilter,What is the requirement for in-line filter during administration of Imfinzi® (durvalumab)?
US - Durvalumab - AD4_Route_IV_InLineFilter,imfinzi filter
US - Durvalumab - AD4_Route_IV_InLineFilter,imfinzi inline filter
US - Durvalumab - IN2_Hepatic,Can Imfinzi® (durvalumab) be used in patients with hepatic impairment?
US - Durvalumab - IN2_Hepatic,imfinzi hepatic impairment
US - Durvalumab - IN2_Hepatic,Imfinzi hepatic dysfunction
US - Durvalumab - IN2_Hepatic,hepatic impairment in imfinzi
US - Durvalumab - IN2_Hepatic,hepatic impairment patients and imfinzi
US - Durvalumab - IN2_Hepatic,Imfinzi use in pattients with hepatic impairment
US - T-DXd - SA1_Safety,Enhertu safety
US - T-DXd - SA1_Safety,safety results of T-DXd
US - T-DXd - SA1_Safety,safety profile of enhertu
US - Osimertinib - IN3_Reproduction_Pregnancy,Can Tagrisso be used in pregnant women?
US - Osimertinib - IN3_Reproduction_Pregnancy,pregnancy
US - Olaparib - EF4_ClinicalTrials_Reproduction_Breast,What is the efficacy of Lynparza in breast cancer?
US - Olaparib - EF4_ClinicalTrials_Reproduction_Breast,Lynparza breast cancer efficacy
US - Olaparib - EF4_ClinicalTrials_Reproduction_Breast,Lynparza efficacy in breast cancer
US - Tremelimumab - SS4_HCPSupport_Resources_PrescribingInformation,Treme PI
US - Tremelimumab - SS4_HCPSupport_Resources_PrescribingInformation,tremelimumab PI
US - Tremelimumab - SS4_HCPSupport_Resources_PrescribingInformation,Imjudo PI
US - Tremelimumab - SS4_HCPSupport_Resources_PrescribingInformation,Imjudo Prescribing information
US - Tremelimumab - SS4_HCPSupport_Resources_PrescribingInformation,Treme Prescribing information
US - Tremelimumab - SS4_HCPSupport_Resources_PrescribingInformation,Treme/IMJUDO Package Insert
US - Osimertinib - EF3_ClinicalTrials_ResistanceMechanisms,What are the main resistance mechanisms when Osimertinib is used in first-line metastatic NSCLC?
US - Osimertinib - EF3_ClinicalTrials_ResistanceMechanisms,mutations at progression
US - Osimertinib - EF3_ClinicalTrials_ResistanceMechanisms,acquired resistance with Tagrisso
US - Osimertinib - EF3_ClinicalTrials_ResistanceMechanisms,mechanisms of resistance
US - Osimertinib - EF3_ClinicalTrials_ResistanceMechanisms,Data of acquired resistance with Tagrisso from FLAURA and/or FLAURA2 trial
US - Osimertinib - USE IN PEDIATRICS,Tagrisso use in pediatrics
US - Osimertinib - USE IN PEDIATRICS,Tagrisso Pediatrics
US - Osimertinib - IN3_PlaceInTherapy_OtherTKI,Should one use other TKI in adjuvant setting and save osimertinib to use after progression?
US - Osimertinib - IN3_PlaceInTherapy_OtherTKI,Should one use other TKI in adjuvant setting and save osimertinib to use after metastases?
US - Osimertinib - IN3_PlaceInTherapy_OtherTKI,waiting to use osimertinib 
US - Olaparib - RE4_PublishedData_PROpel_Safety,What are the safety results of PROpel?
US - Olaparib - RE4_PublishedData_PROpel_Safety,PROpel safety
US - Olaparib - RE4_PublishedData_PROpel_Safety,PROpel safety results
US - Olaparib - RE4_PublishedData_PROpel_Safety,PROpel adverse events
US - Olaparib - RE4_PublishedData_PROpel_Safety,AE PROpel
US - Olaparib - RE4_PublishedData_PROpel_Safety,PROpel AE
US - Olaparib - SS3_ContactPharmaGroup_ESGOCongress, Lynparza ESGO 2022
US - Olaparib - SS3_ContactPharmaGroup_ESGOCongress,ESGO 2022 Lynparza
US - Durvalumab - RE4_PublishedData_CALLA_Safety,What are the safety results from CALLA?
US - Durvalumab - RE4_PublishedData_CALLA_Safety,CALLA safety
US - Durvalumab - RE4_PublishedData_CALLA_Safety,CALLA safety results
US - Durvalumab - RE4_PublishedData_CALLA_Safety,Safety in CALLA
US - Durvalumab - RE4_PublishedData_CALLA_Safety,Safety CALLA
US - Osimertinib - IN3_Reproduction_Lactation,Can Tagrisso be used in women who are breastfeeding?
US - Osimertinib - IN3_Reproduction_Lactation,lactating
US - Osimertinib - IN3_Reproduction_Lactation,lactation
US - Camizestrant - RE3_PublishedData_SERENA1,What is the trial design for SERENA-1
US - Camizestrant - RE3_PublishedData_SERENA1,What are the results for SERENA-1
US - Camizestrant - RE3_PublishedData_SERENA1,SERENA-1 SABCS 2023
US - Osimertinib - SA4_AdverseEvents_CVS_QTcProlongation,QT Prolongation with Tagrisso® (osimertinib)
US - Osimertinib - SA4_AdverseEvents_CVS_QTcProlongation,QTC prolongation
US - Osimertinib - SA4_AdverseEvents_CVS_QTcProlongation,QTC prolonging
US - Osimertinib - SA4_AdverseEvents_CVS_QTcProlongation,QT prolonging 
US - T-DXd - SS4_CONTACTPHARMAGROUP_SABCSCONGRESS_SABCS2023,Enhertu in combination with anastrozole or fluvestrant SABCS 2023
US - T-DXd - SS4_CONTACTPHARMAGROUP_SABCSCONGRESS_SABCS2023,T-DXd in HER2-low mBC SABCS 2023Enhertu SABCS 2023 in HER2-low breast cancer
US - T-DXd - SS4_CONTACTPHARMAGROUP_SABCSCONGRESS_SABCS2023,Enhertu in HER2-low HR+ advanced/metastatic breast cancer
US - T-DXd - SS4_CONTACTPHARMAGROUP_SABCSCONGRESS_SABCS2023,DESTINY-Breast08
US - T-DXd - SS4_CONTACTPHARMAGROUP_SABCSCONGRESS_SABCS2023,Destiny breast 08
US - T-DXd - SS4_CONTACTPHARMAGROUP_SABCSCONGRESS_SABCS2023,Destiny breast 8
US - T-DXd - SS4_CONTACTPHARMAGROUP_SABCSCONGRESS_SABCS2023,DESTINY-Breast08 SABCS
US - T-DXd - SS4_CONTACTPHARMAGROUP_SABCSCONGRESS_SABCS2023,Destiny breast 08 SABCS
US - T-DXd - SS4_CONTACTPHARMAGROUP_SABCSCONGRESS_SABCS2023,Destiny breast 8 SABCS
US - T-DXd - SS4_CONTACTPHARMAGROUP_SABCSCONGRESS_SABCS2023,Enhertu exposure efficacy and safety analysis in HER2 positive mBC
US - T-DXd - SS4_CONTACTPHARMAGROUP_SABCSCONGRESS_SABCS2023,SABCS 2023 efficacy and safety analysis ENHERTU
US - T-DXd - SS4_CONTACTPHARMAGROUP_SABCSCONGRESS_SABCS2023,SABCS 2023 analysis in breast cancer
US - T-DXd - SS4_CONTACTPHARMAGROUP_SABCSCONGRESS_SABCS2023,Enhertu SABCS 2023 analysis in HER2 + mBCDB-02 and 03 SABCS 2023
US - T-DXd - SS4_CONTACTPHARMAGROUP_SABCSCONGRESS_SABCS2023,HER2 positive mBC ENHERTU SABCS 2023
US - T-DXd - SS4_CONTACTPHARMAGROUP_SABCSCONGRESS_SABCS2023,HER2 positive mBc Trastuzumab Deruxtecan SABCS 2023T-DXd HER2 positive mBC SABCS 2023
US - T-DXd - SS4_CONTACTPHARMAGROUP_SABCSCONGRESS_SABCS2023,DESTINY-Breast 02 and 03
US - T-DXd - SS4_CONTACTPHARMAGROUP_SABCSCONGRESS_SABCS2023,Destiny breast 2 and 3 SABCS
US - T-DXd - SS4_CONTACTPHARMAGROUP_SABCSCONGRESS_SABCS2023,Destiny breast 2 and 3
US - T-DXd - SS4_CONTACTPHARMAGROUP_SABCSCONGRESS_SABCS2023,DESTINY-Breast 02 and 03 SABCS
US - T-DXd - DI1_DrugInteractions,Which drugs interact with Enhertu?
US - Olaparib - RE4_PublishedData_PROpel_Abiraterone,Why was abiraterone chosen as the NHA combination partner in the PROpel study?
US - Olaparib - RE4_PublishedData_PROpel_Abiraterone,Rationale for abiraterone in combination therapy lynparza
US - Olaparib - RE4_PublishedData_PROpel_Abiraterone,PROpel combination therapy partner
US - Olaparib - RE4_PublishedData_PROpel_Abiraterone,PROpel abiraterone
US - Olaparib - RE4_PublishedData_PROpel_Abiraterone,Choice of abiraterone chosen as NHA combination partner lynparza
US - Olaparib - RE4_PublishedData_PROpel_Abiraterone,NHA choice in PROpel
US - Olaparib - RE4_PublishedData_PROpel_Abiraterone,PROpel NHA combination partner
US - Durvalumab - RE3_PublishedData_CALLA,CALLA
US - Durvalumab - RE3_PublishedData_CALLA,CALLA results
US - Durvalumab - RE3_PublishedData_CALLA,CALLA study results
US - Durvalumab - RE3_PublishedData_CALLA,CALLA Efficacy results
US - Durvalumab - RE3_PublishedData_CALLA,CALLA Efficacy
US - Durvalumab - RE3_PublishedData_CALLA,Use of durvalamab in cervical cancer
US - Durvalumab - RE3_PublishedData_CALLA,Use of Imfinzi in cervical cancer
US - Acalabrutinib - IN3_CVS_AtrialFibrillation,acalabrutinib in patients with prior atrial fibrillation
US - Acalabrutinib - IN3_CVS_AtrialFibrillation,Calquence and Afib
US - Acalabrutinib - IN3_CVS_AtrialFibrillation,Acalabrutinib and Afib
US - Acalabrutinib - IN3_CVS_AtrialFibrillation,acalabrutinib and atrial fibrillation
US - Acalabrutinib - IN3_CVS_AtrialFibrillation,onset and duration of atrial fibrillation with acalabrutinib
US - Acalabrutinib - IN3_CVS_AtrialFibrillation,Do you have information on the use of acalabrutinib in patients with atrial fibrillation?
US - Olaparib - RE4_PublishedData_LUCY_Safety,Lucy safety
US - Olaparib - RE4_PublishedData_LUCY_Safety,LUCY safety results
US - Olaparib - RE4_PublishedData_LUCY_Safety,LUCY safety
US - Olaparib - RE4_PublishedData_LUCY_Safety,Safety in LUCY
US - Olaparib - RE4_PublishedData_LUCY_Safety,Safety of LUCY
US - Olaparib - RE4_PublishedData_OlympiA_Efficacy,What are the efficacy results from the Olympia trial?
US - Olaparib - RE4_PublishedData_OlympiA_Efficacy,OlympiA efficacy results
US - Olaparib - RE4_PublishedData_OlympiA_Efficacy,OlympiA efficacy
US - Olaparib - RE4_PublishedData_OlympiA_Efficacy,Efficacy in OlympiA
US - Olaparib - RE4_PublishedData_OlympiA_Efficacy,Efficacy of OlympiA
US - T-dxd - SA4_ClinicalTrials_Resp_ILD_Gastric,What is the incidence of ILD in gastric cancer with ENHERTU?
US - T-dxd - SA4_ClinicalTrials_Resp_ILD_Gastric,ILD Gastric cancer
US - Osimertinib - IN3_Condition_Recurrence,What can I use after my patient progresses on Tagrisso?
US - Osimertinib - IN3_Condition_Recurrence,What are the treatment options for when my patient progresses on first-line / second line osimertinib?
US - Osimertinib - IN3_Condition_Recurrence,subsequent therapy
US - Osimertinib - IN3_Condition_Recurrence,progression on tagrisso 
US - T-DXd - AD1_Administration,How is Enhertu administered?   
US - T-DXd - AD1_Administration,How do you dilute Enhertu?
US - T-DXd - AD1_Administration,How do you reconstitute Enhertu?
US - T-DXd - AD1_Administration,How do you prepare Enhertu?
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_Combination,Do you have data on combination therapy with Lynparza in patients with prostate cancer?
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_Combination,combination with olaparib prostate
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_Combination,combination with lynparza prostate
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_Combination,combination therapy with olaparib mCRPC
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_Combination,combination therapy mCRPC
US - Olaparib - SA4_WarningsPrecautions_CNS_BBB,Does Lynparza/olaparib cross the blood-brain barrier?
US - Olaparib - SA4_WarningsPrecautions_CNS_BBB,Use of Lynparza/olaparib in brain metastases
US - Olaparib - SA4_WarningsPrecautions_CNS_BBB,Lynparza/olaparib and brain mets
US - Olaparib - SA4_WarningsPrecautions_CNS_BBB,Lynparza/olaparib in brain disease
US - Olaparib - SA4_WarningsPrecautions_CNS_BBB,Lynparza/olaparib brain penetration
US - T-DXd - IN3_ID_COVID19,COVID 19 related/dose modification
US - Tremelimumab - DI4_Drugs_Oncology_Durvalumab_HCC,Safety of treme in combo with durvalumab in HCC
US - Tremelimumab - DI4_Drugs_Oncology_Durvalumab_HCC,AEs for treme/imjudo with durva/imfinzi in HCC
US - Tremelimumab - DI4_Drugs_Oncology_Durvalumab_HCC,durva treme combo HCC
US - Dato-dxd - RE3_PUBLISHEDDATA_TROPIONLUNG04,TROPION-Lung04
US - Dato-dxd - RE3_PUBLISHEDDATA_TROPIONLUNG04,Tropion lung 04
US - Dato-dxd - RE3_PUBLISHEDDATA_TROPIONLUNG04,Tropion lung 4
US - Camizestrant - CP2_MOA,What is the MOA of camizestrant?
US - Olaparib - EF4_ClinicalTrials_GIT_Pancreatic,What is the efficacy of Lynparza in pancreatic cancer?
US - Olaparib - EF4_ClinicalTrials_GIT_Pancreatic,olaparib efficacy in pancreatic
US - Acalabrutinib - SA4_AdverseEvents_CNS_Headache,headache with acalabrutinib
US - Acalabrutinib - SA4_AdverseEvents_CNS_Headache,management of headache and acalabrutinib
US - Acalabrutinib - SA4_AdverseEvents_CNS_Headache,calquence and headache mangagement with caffeine
US - Acalabrutinib - SA4_AdverseEvents_CNS_Headache,headache and calquence
US - Acalabrutinib - SA4_AdverseEvents_CNS_Headache,Do you have information on the incidence and management of headache with acalabrutinib?
US - T-dxd - RE4_OngoingStudies_DESTINYGastric02_ESMO,What is the trial design of DESTINY-Gastric02?
US - T-dxd - RE4_OngoingStudies_DESTINYGastric02_ESMO,What are the results of DESTINY-Gastric02
US - T-dxd - RE4_OngoingStudies_DESTINYGastric02_ESMO,What are the efficacy/safety results of DESTINY-Gastric02
US - T-dxd - RE4_OngoingStudies_DESTINYGastric02_ESMO,ENHERTU DG02
US - T-dxd - RE4_OngoingStudies_DESTINYGastric02_ESMO,DG02
US - T-dxd - RE4_OngoingStudies_DESTINYGastric02_ESMO,DESTINY-GASTRIC02
US - T-dxd - RE4_OngoingStudies_DESTINYGastric02_ESMO,DG-02
US - Durvalumab - RE3_OngoingStudies_TOPAZ1,What are the results of the TOPAZ-1 trial?
US - Durvalumab - RE3_OngoingStudies_TOPAZ1,TOPAZ-1 results
US - Durvalumab - RE3_OngoingStudies_TOPAZ1,What was the data from TOPAZ-1
US - Durvalumab - RE3_OngoingStudies_TOPAZ1,TOPAZ-1 Dosing regimen
US - Durvalumab - RE3_OngoingStudies_TOPAZ1,Topaz trial information
US - Osimertinib - SA3_AdverseEvents_Detect,AE
US - Osimertinib - SA3_AdverseEvents_Detect,Adverse event
US - Osimertinib - SA3_AdverseEvents_Detect,Report an adverse event
US - T-DXd - RE4_OngoingStudies_J101_HER2Positive,What are the results of J101 trial in HER2 positive breast cancer cohort
US - Olaparib - RE4_PublishedData_PROpel_HRRTesting,How testing for HRRm was conducted in PROpel?
US - Olaparib - RE4_PublishedData_PROpel_HRRTesting,PROpel HRR
US - Olaparib - RE4_PublishedData_PROpel_HRRTesting,PROpel HRRm
US - Olaparib - RE4_PublishedData_PROpel_HRRTesting,PROpel non-HRRm
US - Olaparib - RE4_PublishedData_PROpel_HRRTesting,PROpel testing
US - Olaparib - RE4_PublishedData_PROpel_HRRTesting,PROpel mutation testing
US - Acalabrutinib - SA4_AdverseEvents_CVS_Hypertension,hypertension with acalabrutinib
US - Acalabrutinib - SA4_AdverseEvents_CVS_Hypertension,What is the incidence of hypertension with acalabrutinib.?
US - Acalabrutinib - SA4_AdverseEvents_CVS_Hypertension,Acalabrutinib and hypertension
US - Acalabrutinib - SA4_AdverseEvents_CVS_Hypertension,Management of Hypertension and acalabrutinib
US - Acalabrutinib - SA4_AdverseEvents_CVS_Hypertension,management of hypertension and calquence
US - Acalabrutinib - SA4_AdverseEvents_CVS_Hypertension,hypertension events with calquence
US - Acalabrutinib - SA4_AdverseEvents_CVS_Hypertension,calquence and HT
US - Acalabrutinib - SA4_AdverseEvents_CVS_Hypertension,onset and duration of hypertension with calquence
US - Olaparib - RE4_PublishedData_PROpel_Demographics,What is the difference between patient populations of PROfound and PROpel studies?
US - Olaparib - RE4_PublishedData_PROpel_Demographics,Profound vs PROpel
US - Olaparib - RE4_PublishedData_PROpel_Demographics,PROpel patient population
US - Olaparib - RE4_PublishedData_PROpel_Demographics,PROpel demographics
US - Olaparib - RE4_PublishedData_PROpel_Demographics,Profound patient population
US - Olaparib - RE4_PublishedData_PROpel_Demographics,Profound demographics
US - Tremelimumab - ST2_OutOfSafeTempRange,Temperature Excursions in Treme
US - Tremelimumab - ST2_OutOfSafeTempRange,Treme/Imjudo was left at room temperature for 'x' hours
US - Tremelimumab - ST2_OutOfSafeTempRange,Can treme/Imjudo be used if left at 'x' temp for 'y' hours
US - Osimertinib - RE3_OngoingStudies_SAVANNAH,SAVANNAH
US - Osimertinib - RE3_OngoingStudies_SAVANNAH,SAVANNAH Study
US - Osimertinib - RE3_OngoingStudies_SAVANNAH,SAVANNAH trial 
US - T-DXd - CO1_Cost,What is the cost of Enhertu
US - Durvalumab - RE3_PublishedData_ADRIATIC,What are the results of the ADRIATIC trial?
US - Durvalumab - RE3_PublishedData_ADRIATIC,imfinzi adriatic
US - Acalabrutinib - SA4_WarningsPrecautions_CNS_BBB,acalabrutinib crossing blood-brain barrier
US - Acalabrutinib - SA4_WarningsPrecautions_CNS_BBB,acalabrutinib and CNS penetration
US - Acalabrutinib - SA4_WarningsPrecautions_CNS_BBB,calquence and BBB
US - Acalabrutinib - SA4_WarningsPrecautions_CNS_BBB,Can acalabrutinib cross the blood-brain barrier?  
US - Acalabrutinib - SA4_WarningsPrecautions_CNS_BBB,Does acalabrutinib have CNS penetration?
US - T-DXd - IN1_IndicationsClinicalUse,What is Enhertu® indicated for?
US - T-DXd - IN1_IndicationsClinicalUse,What are the indications of T-DXd?
US - T-DXd - IN1_IndicationsClinicalUse,Uses of enhertu
US - Durvalumab - ST2_HandlingInstructions,How do you handle Imfinzi? MSDS
US - Durvalumab - ST2_HandlingInstructions,imfinzi handling
US - T-dxd - RE3_OngoingStudies_HUDSON,HUDSON trial
US - T-dxd - RE3_OngoingStudies_HUDSON,Enhertu HUDSON
US - T-dxd - RE3_OngoingStudies_HUDSON,T-DXd HUDSON
US - T-dxd - RE3_OngoingStudies_HUDSON,Imfinzi and Enhertu in lung cancer
US - T-dxd - RE3_OngoingStudies_HUDSON,Imfinzi and Enhertu in NSCLC
US - T-dxd - RE3_OngoingStudies_HUDSON,durvalumab and trastuzumab deruxtecan in lung cancer
US - T-dxd - RE3_OngoingStudies_HUDSON,durvalumab and trastuzumab deruxtecan in NSCLC 
US - T-dxd - RE3_OngoingStudies_HUDSON,durvalumab and T-DXd in lung cancer 
US - T-dxd - RE3_OngoingStudies_HUDSON,durvalumab and T-DXd in NSCLC
US - T-DXd - DO2_Variations,General dosage modifications for adverse reactions enhertu
US - T-DXd - DO2_Variations,Dose interruptions for adverse events with Enhertu
US - T-DXd - DO2_Variations,Dose modifications of enhertu during side effects
US - T-DXd - DO2_Variations,Management of enhertu induced adverse events
US - Durvalumab - CO1_Cost,Aquisition cost for durvalumab
US - Durvalumab - CO1_Cost,Cost of durvalumab
US - Osimertinib - AV3_Resp_Recurrence,Will patients with recurrence in ADAURA have access to Tagrisso® (osimertinib)?
US - Camizestrant - SS3_CONTACTPHARMAGROUP_ASCO2023,ASCO 2023 Cami
US - Durvalumab - IN2_Renal,Can Imfinzi® (durvalumab) be used in patients with renal impairment?
US - Durvalumab - IN2_Renal,imfinzi renal impairment
US - Durvalumab - IN2_Renal,durvalumab use in patients with renal impairment
US - Durvalumab - IN2_Renal,Imfinzi use in pattients with Renal impairment
US - T-dxd - RE4_PublishedData_DESTINYGastric01_ESMO,What were the results of the DESTINY-Gastric01 trial?
US - T-dxd - RE4_PublishedData_DESTINYGastric01_ESMO,ENHERTU DG01 results
US - T-dxd - RE4_PublishedData_DESTINYGastric01_ESMO,DG01 results
US - T-dxd - RE4_PublishedData_DESTINYGastric01_ESMO,DG-01 results
US - T-dxd - RE4_PublishedData_DESTINYGastric01_ESMO,DESTINY-GASTRIC01 results
US - T-dxd - RE4_PublishedData_DESTINYGastric01_ESMO,destiny-gastric01 her2 low
US - T-dxd - RE4_PublishedData_DESTINYGastric01_ESMO,dg01 her2 low
US - T-dxd - RE4_PublishedData_DESTINYGastric01_ESMO,Enhertu gastric HER2 low
US - T-dxd - RE3_OngoingStudies_DESTINYGastric03,Destiny Gastric03 ESMO GI 2022
US - T-dxd - RE3_OngoingStudies_DESTINYGastric03,ENHERTU DG03
US - T-dxd - RE3_OngoingStudies_DESTINYGastric03,DESTINY-GASTRIC03
US - T-dxd - RE3_OngoingStudies_DESTINYGastric03,DG03
US - T-dxd - RE3_OngoingStudies_DESTINYGastric03,DG-03
US - Dato-dxd - RE4_OngoingStudies_Oncology_Lung,What is the clinical development plan for Dato-DXd in NSCLC?
US - Dato-dxd - RE4_OngoingStudies_Oncology_Lung,Ongoing studies assessing Dato-DXd in NSCLC
US - Dato-dxd - RE4_OngoingStudies_Oncology_Lung,Ongoing Dato-DXd trials in NSCLC
US - Dato-dxd - RE4_OngoingStudies_Oncology_Lung,Monotherapy Dato-DXd trials in NSCLC
US - Dato-dxd - RE4_OngoingStudies_Oncology_Lung,Combination Dato-DXd trials in NSCLC
US - Dato-dxd - RE4_OngoingStudies_Oncology_Lung,Clinical Development Plan for Dato-DXd in lung cancer
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_Mutations,What is the efficacy of Lynparza in prostate cancer patients with gene mutations?
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_Mutations,What are the endpoints based on the homologous recombination repair mutation (HRRm) in patients with metastatic castration-resistant prostate cancer (mCRPC) ? Lynparza
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_Mutations,Prostate HRRm lynparza
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_Mutations,Prostate HRRm data lynparza
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_Mutations,prostate cancer gene mutation data
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_Mutations,prostate cancer gene data lynparza
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_Mutations,mCRPC gene mutation data
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_Mutations,mCRPC gene data lynparza
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_Mutations,ATM prostate lynparza
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_Mutations,CDK12 prostate lynparza
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_Mutations,gene by gene analysis in prostate lynparza
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_Mutations,olaparib gene mutation data
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_Mutations, Profound gene mutations
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_Mutations,Efficacy in mCRPC with Mutations in PROfound
US - T-dxd - RE4_PUBLISHEDDATA_PANTUMOR_SAFETY,Enhertu pantumor safety
US - T-dxd - RE4_PUBLISHEDDATA_PANTUMOR_SAFETY,DESTINY-PANTUMOR safety
US - T-dxd - RE4_PUBLISHEDDATA_PANTUMOR_SAFETY,DESTINY-PanTumor02 safety
US - T-dxd - RE4_PUBLISHEDDATA_PANTUMOR_SAFETY,DESTINY-PanTumor01 safety
US - Capivasertib - ONGOING STUDIES BREAST CANCER,What is the clinical development plan for capivasertib?
US - Capivasertib - ONGOING STUDIES BREAST CANCER,What are the ongoing studies assessing capivasertib?
US - Capivasertib - ONGOING STUDIES BREAST CANCER,ongoing studies for capivasertib
US - Capivasertib - ONGOING STUDIES BREAST CANCER,clinical development plan for capivasertib
US - Capivasertib - ONGOING STUDIES BREAST CANCER,ongoing trials for capivasertib 
US - Acalabrutinib - IN4_Immune_Ibrutinib_Intolerance,acalabrutinib in patients intolerant to ibrutinib
US - Acalabrutinib - IN4_Immune_Ibrutinib_Intolerance,acalabrutinib in patients relapsed on ibrutinib
US - Acalabrutinib - IN4_Immune_Ibrutinib_Intolerance,calquence in ibrutinib intolerant patientsIs
US - Acalabrutinib - IN4_Immune_Ibrutinib_Intolerance,there any information on the use of acalabrutinib in patients intolerant to ibrutinib or relapsed on ibrutinib?
US - Durvalumab - DE3_Packaging_OverfillVolume,What is the overfill volume for Imfinzi® (durvalumab)?
US - Durvalumab - DE3_Packaging_OverfillVolume,imfinzi overfill
US - Osimertinib - CheckpointInhibitor_Before,Can I use Tagrisso® (osimertinib) after a checkpoint inhibitor?
US - Osimertinib - CheckpointInhibitor_Before,ICI/CPI before osimertinib; nivolumab/pembrolizumab/atezolimumab before osimertinib
US - Osimertinib - CheckpointInhibitor_Before,IO before osimertinib
US - Osimertinib - CheckpointInhibitor_Before,IO before Tagrisso
US - Acalabrutinib - RE4_C_PUBLISHEDDATA_MAIC,MAIC calquence
US - Acalabrutinib - RE4_C_PUBLISHEDDATA_MAIC,MAIC in TN CLLMAIC ASCO 2023 poster
US - Acalabrutinib - RE4_C_PUBLISHEDDATA_MAIC,MAIC in RR CLL
US - Acalabrutinib - RE4_C_PUBLISHEDDATA_MAIC,Do you have any data on the comparison of acalabrutinib vs zanubrutinib in CLL
US - Acalabrutinib - RE4_C_PUBLISHEDDATA_MAIC,acalabrutinib vs zanubrutinib
US - Acalabrutinib - RE4_C_PUBLISHEDDATA_MAIC,calquence vs brukinsa
US - Acalabrutinib - RE4_C_PUBLISHEDDATA_MAIC,acala and zanu
US - Acalabrutinib - RE4_C_PUBLISHEDDATA_MAIC,MAIC iwCLL poster
US - Olaparib - RE4_PublishedData_PROfound_Efficacy,what are the efficacy results of PROfound?
US - Olaparib - RE4_PublishedData_PROfound_Efficacy,PROfound efficacy
US - Olaparib - RE4_PublishedData_PROfound_Efficacy,PROfound efficacy results
US - Olaparib - RE4_PublishedData_PROfound_Efficacy,PROfound efficacy endpoints
US - Olaparib - SA3_AdverseEvents_Heme,What is the rate of hematologic adverse events with Lynparza?  
US - Olaparib - SA3_AdverseEvents_Heme,What are the hematological toxicities with olaparib?
US - Olaparib - SA3_AdverseEvents_Heme,Lynparza/olaparib hematological adverse events
US - Olaparib - SA3_AdverseEvents_Heme,Lynparza/olaparib hematological AEs
US - Olaparib - SA3_AdverseEvents_Heme,Lynparza/olaparib hematological toxicities
US - Olaparib - ST1_StorageStability,How should Lynparza be stored?
US - Olaparib - ST1_StorageStability,"Lynparza was stored outside the recommended temperature, is it still ok to use?"
US - Olaparib - ST1_StorageStability,Lynparza storage
US - Olaparib - ST1_StorageStability,Lynparza tablets storage
US - Olaparib - ST1_StorageStability,Lynparza/olaparib excursion data
US - Olaparib - ST1_StorageStability,Lynparza/olaparib excursion 
US - Olaparib - ST1_StorageStability,Lynparza/olaparib temperature excursion
US - Acalabrutinib - SA4_AdverseEvents_Heme_Lymphocytosis,lymphocytosis and acalabrutinib
US - Acalabrutinib - SA4_AdverseEvents_Heme_Lymphocytosis,elevated lymphocytes with calquence
US - Acalabrutinib - SA4_AdverseEvents_Heme_Lymphocytosis,onset of lymphocytosis with acalabrutinib
US - Acalabrutinib - SA4_AdverseEvents_Heme_Lymphocytosis,duration of lymphocytosis with calquence
US - Acalabrutinib - SA4_AdverseEvents_Heme_Lymphocytosis,What is the incidence of lymphocytosis in patients treated with acalabrutinib? 
US - Acalabrutinib - SA4_AdverseEvents_Heme_Lymphocytosis, What is the approximate onset and duration of lymphocytosis?
US - Acalabrutinib - SA4_AdverseEvents_Heme_Lymphocytosis,Calquence
US - Acalabrutinib - SA4_AdverseEvents_Heme_Lymphocytosis,lymphocytosis and calquence
US - Acalabrutinib - SA4_AdverseEvents_Heme_Lymphocytosis,lymphocytosis with acalabrutinib in CLL and MCL 
US - Camizestrant - SERENA-2 EFFICACY,What is the efficacy results for SERENA-2
US - Camizestrant - SERENA-2 EFFICACY,SERENA-2 efficacy results
US - Olaparib - EF4_ClinicalTrials_Reproduction_Breast_PALB2,Do you have any data in patients with PALB2-mutated breast cancer? Lynparza
US - Olaparib - EF4_ClinicalTrials_Reproduction_Breast_PALB2,Lynparza PALB2 mutated breast cancer
US - Olaparib - EF4_ClinicalTrials_Reproduction_Breast_PALB2,Efficacy of Lynparza in PALB2 mutated breast cancer
US - Olaparib - EF4_ClinicalTrials_Reproduction_Breast_PALB2,Lynparza efficacy difference in BRCA1 vs. BRCA2 ovarian cancer
US - Camizestrant - RE3_PublishedData_SERENA2,What is the trial design for SERENA-2
US - Camizestrant - RE3_PublishedData_SERENA2,SERENA-2 results
US - Camizestrant - RE3_PublishedData_SERENA2,SERENA-2 trial design
US - Osimertinib - RE3_PublishedData_FirstLineTherapy,Tagrisso first line therapy
US - T-dxd - SA4_WarningsPrecautions_GIT_Gastric,What is the safety of ENHERTU in gastric cancer?
US - T-dxd - SA4_WarningsPrecautions_GIT_Gastric,ENHERTU safety gastric cancer
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_ESR,What is the prostate BRCAAway data released at ASCO 2022?
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_ESR,BRCAAway
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_ESR,BRCAAway ASCO 2022
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_ESR,Hussain et al ASCO 2022 lynparza
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_ESR,Hussain ASCO 2022 lynparza
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_ESR,BRCAAway Hussain
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate_ESR,Prostate ESR ASCO 2022 lynparza
US - Olaparib - AV3_Packaging_Bottle,Can I dispense Lynparza in a prescription bottle?
US - Olaparib - AV3_Packaging_Bottle,Remove Lynparza/olaparib from original bottle
US - Olaparib - AV3_Packaging_Bottle,Dispense Lynparza/olparib in prescription bottle
US - Olaparib - AV3_Packaging_Bottle,Store Lynparza/olaparib outside original bottle
US - Olaparib - AV3_Packaging_Bottle,Lynparza pharmacy sub-dispensing
US - Olaparib - AV3_Packaging_Bottle,Lynparza/olaparib Prescription bottle
US - Olaparib - AV3_Packaging_Bottle,olaparib prescription bottle
US - Olaparib - AV3_Packaging_Bottle,lynparza prescription bottle
US - Olaparib - AV3_Packaging_Bottle,olaparib prescription vial
US - Olaparib - AV3_Packaging_Bottle,Lynparza prescription vial
US - Olaparib - AV3_Packaging_Bottle,lynparza prescription bottle
US - Olaparib - AV3_Packaging_Bottle,olaparib prescription bottle
US - Olaparib - AV3_Packaging_Bottle,dispensing lynparza in prescription bottle
US - Olaparib - AV3_Packaging_Bottle,dispensing olaparib in prescription bottle
US - Olaparib - RE4_PublishedData_LUCY_Efficacy,Lucy efficacy
US - Olaparib - RE4_PublishedData_LUCY_Efficacy,LUCY efficacy results
US - Olaparib - RE4_PublishedData_LUCY_Efficacy,LUCY efficacy
US - Olaparib - RE4_PublishedData_LUCY_Efficacy,Efficacy of LUCY
US - Olaparib - RE4_PublishedData_LUCY_Efficacy,Efficacy in LUCY
US - T-dxd - RE3_PublishedData_DESTINYLung01,DESTINY Lung01 Trial Design
US - T-dxd - RE3_PublishedData_DESTINYLung01,Destiny-Lung 01
US - T-dxd - RE3_PublishedData_DESTINYLung01,Destiny Lung 01
US - T-dxd - RE3_PublishedData_DESTINYLung01,Destiny-Lung 1
US - T-dxd - RE3_PublishedData_DESTINYLung01,Destiny Lung 1
US - T-dxd - RE3_PublishedData_DESTINYLung01,DL-01
US - T-dxd - RE3_PublishedData_DESTINYLung01,DL1
US - T-dxd - RE3_PublishedData_DESTINYLung01,DL01
US - T-dxd - RE3_PublishedData_DESTINYLung01,DL 1
US - T-dxd - RE3_PublishedData_DESTINYLung01,DL 01
US - Osimertinib - TE1_TestingMonitoring,Which patients should I test?
US - Osimertinib - TE1_TestingMonitoring,who should be tested
US - Osimertinib - TE1_TestingMonitoring,molecular testing
US - Osimertinib - TE1_TestingMonitoring,when should I test
US - Osimertinib - TE1_TestingMonitoring,HRD testing in tagrisso
US - Osimertinib - TE1_TestingMonitoring,What is HRD testing in tagrisso
US - Osimertinib - TE1_TestingMonitoring,info about HRD testing tagrisso
US - Osimertinib - TE1_TestingMonitoring,tagrisso What is HRD testing
US - Olaparib - IN3_Procedures_Radiation,Can Lynparza be used with radiation therapy?
US - Olaparib - IN3_Procedures_Radiation,Lynparza in combination with radiation
US - Olaparib - IN3_Procedures_Radiation,Lynparza in combination with radiotherapy
US - Acalabrutinib - IN3_Heme_FL,Calquence use in follicular lymphoma
US - Acalabrutinib - IN3_Heme_FL,Data on the use of acalabrutinib in patients with Follicular Lymphoma (FL)
US - Acalabrutinib - IN3_Heme_FL,Acalabrutinib and FL
US - Acalabrutinib - IN3_Heme_FL,Calquence and follicular lymphoma
US - Acalabrutinib - IN3_Heme_FL,Follicular lymphoma data ASH 2022
US - Acalabrutinib - IN3_Heme_FL,Acalabrutinib and follicular lymphoma ASH 2022
US - Acalabrutinib - IN3_Heme_FL,ASH 2023 follicular lymphoma
US - Acalabrutinib - IN3_Heme_FL,ASH 2023 Congress materials FL
US - Acalabrutinib - IN3_Heme_FL,ASH 2023 Calquence FL
US - Osimertinib - DI3_Procedure_Radiation,Can I use Osimertinib with radiation?
US - Osimertinib - DI3_Procedure_Radiation,coadministration/conjunction with radiation therapy/tx
US - Osimertinib - DI3_Procedure_Radiation,radiation
US - Osimertinib - DI3_Procedure_Radiation,tagrisso and radiation
US - Osimertinib - DI3_Procedure_Radiation,tagrisso and radiation therapy
US - Olaparib - AD4_Coadministration_Vaccines_COVID,Can Lynparza be administered with COVID-19 vaccines?
US - Olaparib - AD4_Coadministration_Vaccines_COVID,Can Olaparib be administered with COVID-19 vaccines?
US - Olaparib - AD4_Coadministration_Vaccines_COVID,Lynparza with COVID vaccine
US - Olaparib - AD4_Coadministration_Vaccines_COVID,Olaparib with COVID vaccine
US - Olaparib - AD4_Coadministration_Vaccines_COVID,Lynparza/olaparib with COVID-19 vaccine
US - Olaparib - AD4_Coadministration_Vaccines_COVID,Administration of Lynparza/olaparib with Covid-19 vaccine
US - Olaparib - AD4_Coadministration_Vaccines_COVID,Administration of Lynparza with Covid vaccine
US - Olaparib - AD4_Coadministration_Vaccines_COVID,Administration of olaparib with Covid vaccine
US - Olaparib - RE4_PublishedData_OreO_Safety,AWhat is the safety of the OReO study?
US - Olaparib - RE4_PublishedData_OreO_Safety,OReO safety results
US - Olaparib - RE4_PublishedData_OreO_Safety,OReO safety
US - Olaparib - RE4_PublishedData_OreO_Safety,Safety in OReO
US - Olaparib - RE4_PublishedData_OreO_Safety,Safety of OReO
US - Durvalumab - EF4_ClinicalTrials_Resp_LSSCLC,Trials in LS-SCLC
US - Durvalumab - EF4_ClinicalTrials_Resp_LSSCLC,imfinzi lssclc
US - Durvalumab - EF4_ClinicalTrials_Resp_LSSCLC,imfinzi ls-sclc
US - Olaparib - RE3_PublishedData_OlympiA,Olympia trial
US - Olaparib - RE3_PublishedData_OlympiA,OlympiA study results
US - Olaparib - RE3_PublishedData_OlympiA,OlympiA  results
US - Olaparib - RE3_PublishedData_OlympiA,OlympiA data
US - Acalabrutinib - DI3_Drugs_Anticoagulants,Acalabrutinib and anticoagulants
US - Acalabrutinib - DI3_Drugs_Anticoagulants,Acalabrutinib and antiplatelets
US - Acalabrutinib - DI3_Drugs_Anticoagulants,Acalabrutinib and antithrombotic
US - Acalabrutinib - DI3_Drugs_Anticoagulants,Calquence and anticoagulants
US - Acalabrutinib - DI3_Drugs_Anticoagulants,Calquence and antiplatelets
US - Acalabrutinib - DI3_Drugs_Anticoagulants,Do you have any information on the use of acalabrutinib in patients receiving  anticoagulants/antiplatelets/antithrombotic?
US - Acalabrutinib - DI3_Drugs_Anticoagulants,Calquence and antithrombotic
US - Durvalumab - EF3_ClinicalTrials_MetastaticNSCLC,What trials are available for Imfinzi® (durvalumab) in metastatic NSCLC?
US - Durvalumab - EF3_ClinicalTrials_MetastaticNSCLC,What are the trials in metastatic NSCLC for Imfinzi?
US - Durvalumab - EF3_ClinicalTrials_MetastaticNSCLC,Imfinzi metastatic NSCLC trials
US - Osimertinib - CO3_Support_FinancialAssistance,Is there financial assistance for Tagrisso® (osimertinib)?
US - Osimertinib - CO3_Support_FinancialAssistance,tagrisso and financial aid
US - T-dxd - RE3_PUBLISHEDDATA_DESTINYBREAST08,DB08
US - T-dxd - RE3_PUBLISHEDDATA_DESTINYBREAST08,Destiny-B08
US - T-dxd - RE3_PUBLISHEDDATA_DESTINYBREAST08,Destiny-Breast 08
US - T-dxd - RE3_PUBLISHEDDATA_DESTINYBREAST08,Trastuzumab Deruxtecan-DB08
US - T-dxd - RE3_PUBLISHEDDATA_DESTINYBREAST08,Enhertu-DB08
US - T-dxd - RE3_PUBLISHEDDATA_DESTINYBREAST08,Trastuzumab Deruxtecan-Destiny Breast 08
US - T-dxd - RE3_PUBLISHEDDATA_DESTINYBREAST08,DB08-study design
US - T-dxd - RE3_PUBLISHEDDATA_DESTINYBREAST08,Enhertu- Destiny Breast 08
US - T-dxd - RE3_PUBLISHEDDATA_DESTINYBREAST08,Combination with ana or fulv in HER2-low HR+ mBC
US - T-dxd - RE3_PUBLISHEDDATA_DESTINYBREAST08,Overview of DB08
US - T-dxd - RE3_PUBLISHEDDATA_DESTINYBREAST08, Overview of Destiny-Breast 08
US - T-dxd - RE3_PUBLISHEDDATA_DESTINYBREAST08,DB08-efficacy data
US - T-dxd - RE3_PUBLISHEDDATA_DESTINYBREAST08,DB08-safety data
US - Capivasertib - CAPITELLO-292,What is the trial design for Capitello-292?
US - Capivasertib - CAPITELLO-292,Capitello-292 trial design
US - Capivasertib - CAPITELLO-292,Capitello-292 study overview 
US - Acalabrutinib - SA2_AEManagement,management of adverse event with calquence
US - Acalabrutinib - SA2_AEManagement,calquence dose modifications for adverse events
US - Acalabrutinib - SA2_AEManagement,AE management and acalabrutinib
US - Acalabrutinib - SA2_AEManagement,What are the recommended dose modifications for patients on acalabrutinib experiencing thrombocytopenia/neutropenia/anemia?
US - Acalabrutinib - SA2_AEManagement,What to do in the case of an adverse event? Calquence
US - Acalabrutinib - SA2_AEManagement,Do you have information on the incidence and management of headache with acalabrutinib?
US - Durvalumab - RE3_PUBLISHEDDATA_DUO-E,DUO-E study
US - Durvalumab - RE3_PUBLISHEDDATA_DUO-E,DUO-E efficacy
US - Durvalumab - RE3_PUBLISHEDDATA_DUO-E,Efficacy of DUO-E
US - Durvalumab - RE3_PUBLISHEDDATA_DUO-E,Efficacy results DUO-E
US - Durvalumab - RE3_PUBLISHEDDATA_DUO-E,Efficacy in DUO-E
US - Durvalumab - RE3_PUBLISHEDDATA_DUO-E,Durvalumab DUO-E study
US - Durvalumab - RE3_PUBLISHEDDATA_DUO-E,Imfinzi DUO-E study
US - Camizestrant - RE4_PublishedData_SERENA1_Efficacy,What is the efficacy results for SERENA-1?
US - Durvalumab - RE3_OngoingStudies_CLOVER,What are the results of CLOVER?
US - Durvalumab - RE3_OngoingStudies_CLOVER,imfinzi clover
US - Durvalumab - RE3_OngoingStudies_POSEIDON,POSEIDON trial design
US - Durvalumab - RE3_OngoingStudies_POSEIDON,Do you have information on POSEIDON
US - Durvalumab - RE3_OngoingStudies_POSEIDON,POSEIDON 4-yr OS
US - Durvalumab - RE3_OngoingStudies_POSEIDON,imfinzi poseidon
US - Durvalumab - RE3_OngoingStudies_POSEIDON,POSEIDON 5 year OS
US - Durvalumab - RE3_OngoingStudies_POSEIDON,POSEIDON ESMO IO
US - Acalabrutinib - IN3_Heme_DLBCL,acalabrutinib in DLBCL
US - Acalabrutinib - IN3_Heme_DLBCL,Calquence in diffuse large B-cell lymphoma
US - Acalabrutinib - IN3_Heme_DLBCL,Acalabrutinib in ACE-LY-001
US - Acalabrutinib - IN3_Heme_DLBCL,Acalabrutinib in ACE-LY-002
US - Acalabrutinib - IN3_Heme_DLBCL,Can acalabrutinib be used for patients with DLBCL?
US - T-dxd - RE3_PUBLISHEDDATA_PANTUMOR,Enhertu PanTumor
US - T-dxd - RE3_PUBLISHEDDATA_PANTUMOR,Enhertu pan-tumor
US - T-dxd - RE3_PUBLISHEDDATA_PANTUMOR,Enhertu DESTINY-PANTUMOR
US - T-dxd - RE3_PUBLISHEDDATA_PANTUMOR,DESTINY-PanTumor02
US - T-dxd - RE3_PUBLISHEDDATA_PANTUMOR,DESTINY-PanTumor01
US - T-dxd - RE3_PUBLISHEDDATA_PANTUMOR,DESTINY-PANTUMOR results
US - T-dxd - RE3_PUBLISHEDDATA_PANTUMOR,DESTINY-PanTumor results
US - T-dxd - RE3_PUBLISHEDDATA_PANTUMOR,DESTINY-PanTumor02 results
US - T-dxd - RE3_PUBLISHEDDATA_PANTUMOR,DESTINY-PanTumor01 results
US - Osimertinib - RE2_ParticipationOpportunity,Enrollment in TAGRISSO clinical trials?
US - Osimertinib - RE2_ParticipationOpportunity,participation in trial/study
US - Osimertinib - SS3_PatientSupport_EAP,Help with EAP
US - Dato-dxd - RE3_PUBLISHEDDATA_TROPIONLUNG01,TROPION-Lung01 ELCC
US - Dato-dxd - RE3_PUBLISHEDDATA_TROPIONLUNG01,Tropion lung 01 ELCC
US - Dato-dxd - RE3_PUBLISHEDDATA_TROPIONLUNG01,Tropion lung 1 ELCC
US - Dato-dxd - RE3_PUBLISHEDDATA_TROPIONLUNG01,TROPION-Lung01 nonsquamous
US - Dato-dxd - RE3_PUBLISHEDDATA_TROPIONLUNG01,Tropion lung 1 nonsquamous
US - Dato-dxd - RE3_PUBLISHEDDATA_TROPIONLUNG01,TROPION-Lung01 Study Results
US - Olaparib - RE3_PublishedData_PROfound,What is the efficacy and safety in the Profound trial?
US - Olaparib - RE3_PublishedData_PROfound,What are the results of the PROfound trial?
US - Olaparib - RE3_PublishedData_PROfound,What is the trial design of PROfound?
US - Olaparib - RE3_PublishedData_PROfound,PROfound
US - Olaparib - RE3_PublishedData_PROfound,PROfound endpoints
US - Olaparib - RE3_PublishedData_PROfound,PROfound data
US - Olaparib - RE3_PublishedData_PROfound,olaparib prostate monotherapy
US - Olaparib - RE3_PublishedData_PROfound,PROfound endpoints data
US - Durvalumab - RE3_OngoingStudies_PAC4,Details on study design of PACIFIC 4
US - Durvalumab - RE3_OngoingStudies_PAC4,Tell me about the PAC4 study
US - Durvalumab - RE3_OngoingStudies_PAC4,imfinzi pac4
US - Durvalumab - RE3_OngoingStudies_PAC4,imfinzi pacific 4
US - Olaparib - EF4_ClinicalTrials_Reproduction_Ovarian_NonBRCA,Is there any data in LYNPARZA in patients with ovarian cancer who do not have a BRCA mutation?
US - Olaparib - EF4_ClinicalTrials_Reproduction_Ovarian_NonBRCA,Lynparza in non-BRCA ovarian cancer
US - Camizestrant - RE2_OngoingStudies,What is the clinical development plan for camizestrant
US - Camizestrant - RE2_OngoingStudies,What are the ongoing studies assessing camizestrant?
US - Durvalumab - RE3_PUBLISHEDDATA_LATIFY,LATIFY
US - Durvalumab - RE3_PUBLISHEDDATA_LATIFY,imfinzi LATIFY
US - Durvalumab - RE3_PUBLISHEDDATA_LATIFY,imfinzi LATIFY TIP
US - Durvalumab - RE3_PUBLISHEDDATA_LATIFY,imfinzi latify trial in progress
US - Durvalumab - RE3_PUBLISHEDDATA_LATIFY,imfinzi LATIFY asco 2023
US - Acalabrutinib - SA3_AdverseEvents_MostCommon,most common adverse events with acalabrutinib
US - Acalabrutinib - SA3_AdverseEvents_MostCommon,AEs reported in CLL and MCL trials
US - Acalabrutinib - SA3_AdverseEvents_MostCommon,AE with calquence in CLL
US - Acalabrutinib - SA3_AdverseEvents_MostCommon,AE with calquence in MCL
US - Acalabrutinib - SA3_AdverseEvents_MostCommon,What are the most common adverse events? Calquence
US - Olaparib - RE3_PublishedData_LUCY,LUCY
US - Olaparib - RE3_PublishedData_LUCY,LUCY study results
US - Olaparib - RE3_PublishedData_LUCY,LUCY results
US - Olaparib - RE3_PublishedData_LUCY,LUCY data
US - Olaparib - RE3_PublishedData_POLO,What is the efficacy and safety of Lynparza in the POLO trial?
US - Olaparib - RE3_PublishedData_POLO,POLO
US - Olaparib - RE3_PublishedData_POLO,POLO trial
US - Olaparib - RE3_PublishedData_POLO,POLO endpoints
US - Olaparib - RE3_PublishedData_POLO,POLO endpoints data
US - Olaparib - RE3_PublishedData_POLO,POLO data
US - T-DXd - DE1_Description,Tell me about Enhertu
US - Durvalumab - DO3_Variations_FixedDosing,What data is available to support the use of Imfinzi® (durvalumab) fixed dosing every 4 weeks?
US - Olaparib - CP2_MOA,What is the mechanism of action for Lynparza?
US - Olaparib - CP2_MOA,What is the mechanism of action for olaprib?
US - Olaparib - CP2_MOA,MOA of Lynparza
US - Olaparib - CP2_MOA,MOA of olaparib
US - Olaparib - CP2_MOA,mechanism of action for Lynparza
US - Olaparib - CP2_MOA,mechanism of action for olaparib
US - T-dxd - RE2_ParticipationOpportunity,How do I enroll my patients in ENHERTU clinical trials?
US - Osimertinib - IN2_Hepatic,Can I use Tagrisso in patients with hepatic impairment?
US - Osimertinib - IN2_Hepatic,Liver impairment
US - Osimertinib - IN2_Hepatic,Liver disease
US - Osimertinib - IN2_Hepatic,Hepatic disease
US - Osimertinib - SA4_AdverseEvents_Reproduction_Fertility,Can Tagrisso be used in patients with reproductive potential
US - Osimertinib - SA4_AdverseEvents_Reproduction_Fertility,fertility
US - Durvalumab - IN3_Hepatic_BTC,Imfinzi use in BTC (biliary tract carcinoma)
US - Durvalumab - IN3_Hepatic_BTC,Imfinzi use in biliary tract disease
US - Capivasertib - AD1_ADMINISTRATION,Capivasertib administration
US - Capivasertib - AD1_ADMINISTRATION,TRUQAP administration
US - Capivasertib - AD1_ADMINISTRATION,Capivasertib Dose
US - Capivasertib - AD1_ADMINISTRATION,Capivasertib dosing
US - Capivasertib - AD1_ADMINISTRATION,Capivasertib dosing schedule
US - Capivasertib - AD1_ADMINISTRATION,TRUQAP dose
US - Capivasertib - AD1_ADMINISTRATION,TRUQAP dosing
US - Capivasertib - AD1_ADMINISTRATION,TRUQAP dosing schedule
US - Osimertinib - CD3_Pathophysiology_EGFRm,How many patients with resectable disease will have EGFRm?
US - Durvalumab - AD3_Coadministration_Vaccines,Can you give Imfinzi® (durvalumab) with vaccines?
US - Durvalumab - AD3_Coadministration_Vaccines,Dimfinzi vaccine(s)
US - Durvalumab - ST1_StorageStability,What are the storage recommendations for Imfinzi® (durvalumab)?
US - Durvalumab - ST1_StorageStability,What are the allowed temperature excursions? Imfinzi
US - Durvalumab - ST1_StorageStability,Imfinzi BUD
US - Durvalumab - ST1_StorageStability,Imfinzi Beyond Use Date
US - Acalabrutinib - SS4_HCPSupport_Resources_PrescribingInformation,calquence tablet PI
US - Acalabrutinib - SS4_HCPSupport_Resources_PrescribingInformation,Calquence capsule PI
US - Acalabrutinib - SS4_HCPSupport_Resources_PrescribingInformation,calquence label information
US - Acalabrutinib - SS4_HCPSupport_Resources_PrescribingInformation,Calquence tablet Prescribing information (PI)
US - Acalabrutinib - SS4_HCPSupport_Resources_PrescribingInformation,Calquence capsule Prescribing information (PI)
US - Acalabrutinib - SS4_HCPSupport_Resources_PrescribingInformation,Calquence new formulation PI
US - T-DXd - ST1_StorageStability,How should ENHERTU be stored?
US - T-DXd - ST1_StorageStability,ENHERTU temperature excursion
US - Durvalumab - AD3_Timing_After42Days,Can you use Imfinzi® (durvalumab) more than 42 days after chemoradiotherapy?
US - Durvalumab - AD3_Timing_After42Days,What are the outcomes if you use durvalumab more than 42 days after chemoradiotherapy?
US - Acalabrutinib - DO4_Variations_Procedures_Surgery,dose adjustments of acalabrutinib before/after surgery?
US - Acalabrutinib - DO4_Variations_Procedures_Surgery,calquence dose modification after surgery
US - Acalabrutinib - DO4_Variations_Procedures_Surgery,calquence dose modifications before surgery
US - Acalabrutinib - DO4_Variations_Procedures_Surgery,Is there information on dose modification/adjustments of acalabrutinib before/after surgery?
US - T-DXd - AD3_Coadministration_Chloroquine,Enhertu use with chloroquine/hydroxychloroquine?
US - Olaparib - AD1_Administration,How is Lynparza administered?
US - Olaparib - AD1_Administration,Administration of olaparib
US - Olaparib - AD1_Administration,Olaparib administration
US - Olaparib - AD1_Administration,Lynparza administration
US - Olaparib - AD1_Administration,Dosing of Lymparza
US - Olaparib - AD1_Administration,Dosing of olaparib
US - Olaparib - AD1_Administration,olaparib dosage
US - Olaparib - AD1_Administration,Lynparza dosage
US - Olaparib - IN3_Procedures_Surgery,Is there any information on the timing of Lynparza administration around surgery?
US - Olaparib - IN3_Procedures_Surgery,"Should Lynparza be held prior to, or after surgery?"
US - Olaparib - IN3_Procedures_Surgery,Restarting Lynparza after surgery
US - Olaparib - IN3_Procedures_Surgery,Stopping Lynparza before surgery
US - Olaparib - IN3_Procedures_Surgery,Lynparza and surgery
US - Olaparib - IN3_Procedures_Surgery,Is there any information on the timing of olaparib administration around surgery?
US - Olaparib - IN3_Procedures_Surgery,"Should olaparib be held prior to, or after surgery?"
US - Olaparib - IN3_Procedures_Surgery,Restarting olaparib after surgery
US - Olaparib - IN3_Procedures_Surgery,Stopping olaparib before surgery
US - Olaparib - IN3_Procedures_Surgery,olaparib and surgery
US - Durvalumab - RE3_OngoingStudies_PACIFIC2,PACIFIC 2 trial design
US - Durvalumab - RE3_OngoingStudies_PACIFIC2,What were the results of the PACIFIC2 study
US - Durvalumab - RE3_OngoingStudies_PACIFIC2,imfinzi pac2
US - Durvalumab - RE3_OngoingStudies_PACIFIC2,imfinzi pacific 2
US - Olaparib - RE4_PublishedData_PROfound_HRQoL,What are the health-related quality of life results from PROfound?
US - Olaparib - RE4_PublishedData_PROfound_HRQoL,Profound HRQoL
US - Olaparib - RE4_PublishedData_PROfound_HRQoL,profound hrqol
US - Olaparib - RE4_PublishedData_PROfound_HRQoL,profound health related quality of life
US - Olaparib - RE4_PublishedData_PROfound_HRQoL,profound health related QoL
US - Capivasertib - CAPITELLO-291 SAFETY,What are the most common AEs in Capitello-291?
US - Capivasertib - CAPITELLO-291 SAFETY,What are the most common AEs in Capitello-291?
US - Capivasertib - CAPITELLO-291 SAFETY,What are the AEs with capivasertib?
US - Capivasertib - CAPITELLO-291 SAFETY,Safety of capivasertib?
US - Capivasertib - CAPITELLO-291 SAFETY,Most common AEs with capivasertib?
US - Capivasertib - CAPITELLO-291 SAFETY,Capitello-291 safety profile
US - Osimertinib - RE4_PublishedData_ADAURA_Chemotherapy,Why didn't all patients in the ADAURA trial receive chemotherapy?
US - Osimertinib - RE4_PublishedData_ADAURA_Chemotherapy,ADAURA/adjuvant trial chemotherapy received
US - Osimertinib - RE4_PublishedData_ADAURA_Chemotherapy,adaura patients given chemo
US - Osimertinib - RE4_PublishedData_ADAURA_Chemotherapy,adaura chemo/chemotherapy population
US - Osimertinib - RE4_PublishedData_ADAURA_Chemotherapy,adaura chemo/chemotherapy patients
US - Osimertinib - RE4_PublishedData_ADAURA_Chemotherapy,Outcomes/results/efficacy for patients who did/didn't get adjuvant chemo in ADAURA
US - Osimertinib - SA2_AdverseEvents,What are the side effects of Tagrisso?
US - Osimertinib - SA2_AdverseEvents,adverse effects
US - Osimertinib - SA2_AdverseEvents,adverse reactions
US - Osimertinib - SA2_AdverseEvents,most common AE/ADRS
US - Osimertinib - SA2_AdverseEvents,AE
US - Osimertinib - SA2_AdverseEvents,ADR
US - Durvalumab - CI1_Contraindications,What are the contraindications of Imfinzi?
US - Durvalumab - CI1_Contraindications,imfinzi contraindications
US - Acalabrutinib - IN3_Subgroup_Pediatrics,calquence and pediatric patients
US - Acalabrutinib - IN3_Subgroup_Pediatrics,Acalabrutinib in patients less than 18 years
US - Acalabrutinib - IN3_Subgroup_Pediatrics,Calquence in childrenIs
US - Acalabrutinib - IN3_Subgroup_Pediatrics,Calquence indicated in pediatrics patients?
US - T-dxd - IN3_GIT_Gastric,ENHERTU and gastric cancer
US - T-dxd - IN3_GIT_Gastric,What is the efficacy of ENHERTU in gastric cancer?
US - T-dxd - IN3_GIT_Gastric,ENHERTU Gastric cancer trials
US - Durvalumab - AD3_Coadministration_COVIDVaccine,Can a patient on Imfinzi® (durvalumab) receive a COVID vaccine?
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,IMFINZI/IMJUDO ASCO 2024
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,IMFINZI ASCO
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,IMFINZI ASCO 2024
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,IMFINZI ASCO congress
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,IMFINZI ASCO conference posters
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,Durvalumab/tremelimumab ASCO 2024 posters
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,Hepatocellular carcinoma ASCO 2024
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,hepatocellular cancer ASCO 2024
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,HCC ASCO 2024
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,liver cancer data ASCO 2024
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,Durvalumab ASCO 2024 posters
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,Imfinzi AEGEAN ASCO
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,Imfinzi AEGEAN ASCO 2024
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,AEGEAN ASCO
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,AEGEAN ASCO 2024
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,Imfinzi ADRIATIC ASCO
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,Imfinzi ADRIATIC ASCO 2024
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,ADRIATIC ASCO
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,ADRIATIC ASCO 2024
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,Imfinzi COAST ASCO
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,Imfinzi COAST ASCO 2024
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,TRITON COAST
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,TRITON COAST 2024
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,Imfinzi eVOLVE-Lung02 ASCO
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,Imfinzi eVOLVE-Lung02 ASCO 2024
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,eVOLVE-Lung02 ASCO
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,eVOLVE-Lung02 ASCO 2024
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,Imfinzi TRITON ASCO
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,Imfinzi TRITON ASCO 2024
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,TRITON ASCO
US - Durvalumab - SS4_CONTACTPHARMAGROUP_ASCOCONGRESS_ASCO2024,TRITON ASCO 2024
US - Olaparib - RE4_PublishedData_PAOLA1_Safety,What is the safety of PAOLA-1
US - Olaparib - RE4_PublishedData_PAOLA1_Safety,PAOLA-1 safety
US - Olaparib - RE4_PublishedData_PAOLA1_Safety,"PAOLA-1 safety results,"
US - Olaparib - RE4_PublishedData_PAOLA1_Safety,PAOLA-1 updated safety
US - Olaparib - RE4_PublishedData_PAOLA1_Safety,PAOLA-1 updated safety results
US - Olaparib - RE4_PublishedData_PAOLA1_Safety,PAOLA-1 long-term safety
US - Olaparib - RE4_PublishedData_PAOLA1_Safety,PAOLA-1 5 year safety data
US - Olaparib - RE4_PublishedData_PAOLA1_Safety,PAOLA-1 5-year safety
US - Olaparib - RE4_PublishedData_PAOLA1_Safety,PAOLA-1 long-term safety data
US - Durvalumab - AD4_Coadministration_Oncology_PD1Inhibitors,Combination treatment with another checkpoint inhibitor
US - Olaparib - RE3_PUBLISHEDDATA_DUO-O,DUO-O
US - Olaparib - RE3_PUBLISHEDDATA_DUO-O,DUO-O study
US - Olaparib - RE3_PUBLISHEDDATA_DUO-O,What is the Study deisgn of DUO-O
US - Olaparib - RE3_PUBLISHEDDATA_DUO-O,Lynparza DUO-O
US - Olaparib - RE3_PUBLISHEDDATA_DUO-O,Imfinzi DUO-O
US - Durvalumab - RE4_PublishedData_HIMALAYA_Efficacy,What were the efficacy outcomes from HIMALAYA
US - Durvalumab - RE4_PublishedData_HIMALAYA_Efficacy,Efficacy results/data for Himalaya
US - Durvalumab - RE4_PublishedData_HIMALAYA_Efficacy,Overall survival (OS) results in Himalaya
US - Durvalumab - RE4_PublishedData_HIMALAYA_Efficacy,Objective response rate (ORR) results in Himalaya
US - Durvalumab - RE4_PublishedData_HIMALAYA_Efficacy,Progression free survival (PFS) results in Himalaya
US - Durvalumab - RE4_PublishedData_HIMALAYA_Efficacy,Updated Overall survival data for the HIMALAYA trial
US - Durvalumab - RE4_PublishedData_HIMALAYA_Efficacy,Updated efficacy data for the HIMALAYA trial
US - T-dxd - IN3_GIT_CRC,Enhertu and colorectal cancer
US - T-dxd - IN3_GIT_CRC,What is the efficacy of Enhertu® in colorectal cancer?
US - T-dxd - IN3_GIT_CRC,ENHERTU CRC 
US - Tremelimumab- DI4_Drugs_Oncology_Durvalumab,Safety of treme in combo with durvalumab?
US - Tremelimumab- DI4_Drugs_Oncology_Durvalumab,treme safety
US - Tremelimumab- DI4_Drugs_Oncology_Durvalumab,AEs with treme/imjudo and durvalumab/imfinzi
US - T-DXd - SA3_AdverseEvents_Alopecia_Breast,What is the occurrence of Alopecia? ;
US - T-DXd - SA3_AdverseEvents_Alopecia_Breast,Alopecia and T-DXd;
US - T-DXd - SA3_AdverseEvents_Alopecia_Breast,Enhertu and Alopecia.
US - T-dxd - RE4_PublishedData_DESTINYLung01_HER2,DESTINY-Lung01 CNS
US - T-dxd - RE4_PublishedData_DESTINYLung01_HER2,DESTINY-Lung01 CNS mets/metastasis/metastases
US - T-dxd - RE4_PublishedData_DESTINYLung01_HER2,DESTINY-Lung01 brain mets/metastasis/metastases
US - T-dxd - RE4_PublishedData_DESTINYLung01_HER2,DESTINY-Lung01 subgroup analysis
US - T-dxd - RE4_PublishedData_DESTINYLung01_HER2,DESTINY-Lung01 HER2-mutant
US - T-dxd - RE4_PublishedData_DESTINYLung01_HER2,DESTINY-Lung01 Cohort 2
US - T-dxd - RE4_PublishedData_DESTINYLung01_HER2,"Apply all variations in the above utterances: Destiny-Lung 01, Destiny Lung 01, Destiny-Lung 1, Destiny Lung 1, DL-01, DL1, DL01, DL 1, DL 01"
US - Durvalumab - DO1_Dosing,Recommended dosage of Imfinzi® (durvalumab)
US - Durvalumab - DO1_Dosing,dosage for approved indications
US - Durvalumab - DO1_Dosing,imfinzi dose
US - Durvalumab - DO1_Dosing,imfinzi dosing
US - Capivasertib - CAPITELLO-290,Capitello-290 trial design
US - Capivasertib - CAPITELLO-290,What is the trial design for Capitello-290?
US - Capivasertib - CAPITELLO-290,Capitello-290 study overview 
US - Durvalumab - RE4_OngoingStudies_COAST,Summarizes COAST results
US - Durvalumab - RE4_OngoingStudies_COAST,imfinzi COAST
US - Durvalumab - RE3_OngoingStudies_PAC9,Details on study design of PACIFIC 9
US - Durvalumab - RE3_OngoingStudies_PAC9,Purpose of the PAC9 study
US - Durvalumab - RE3_OngoingStudies_PAC9,imfinzi pac9
US - Durvalumab - RE3_OngoingStudies_PAC9,imfinzi pacific 9
US - Osimertinib - DO3_Variations_BrainMets,Is 160 mg of osimertinib better than 80 mg for brain mets?
US - Osimertinib - DO3_Variations_BrainMets,higher dose of Tagrisso for brain mets/metastases
US - Osimertinib - DO3_Variations_BrainMets,tagrisso dose for brain metastases
US - Osimertinib - DO3_Variations_BrainMets,tagrisso brain metastases dose
US - Osimertinib - DI1_DrugInteractions,What are the drug drug interactions to be aware of with osimertinib?
US - Osimertinib - DI1_DrugInteractions,"DDI, DI"
US - Osimertinib - DI1_DrugInteractions,osimertinib plus x
US - Osimertinib - DI1_DrugInteractions,concomitant use
US - Osimertinib - DI1_DrugInteractions,drug interactions
US - Osimertinib - DI1_DrugInteractions,interactions
US - Osimertinib - DO3_Variations_CNS,What dose should I use for CNS disease?
US - Osimertinib - DO3_Variations_CNS,How can I use osimertinib for CNS progression/metastasis? 
US - Capivasertib - SS4_HCPSUPPORT_RESOURCES_PRESCRIBINGINFORMATION,TRUQAP prescribing information
US - Capivasertib - SS4_HCPSUPPORT_RESOURCES_PRESCRIBINGINFORMATION,TRUQAP PI
US - Capivasertib - SS4_HCPSUPPORT_RESOURCES_PRESCRIBINGINFORMATION,capivasertib PI
US - Olaparib - EF1_Efficacy,What is the efficacy of Lynparza?
US - Olaparib - EF1_Efficacy,Lynparza/olparib efficacy
US - Olaparib - EF1_Efficacy,1Efficacy of Lynparza/olaparib
US - Acalabrutinib - CO3_Support_FinancialAssistance,Is there financial assistance for Calquence?
US - Acalabrutinib - CO3_Support_FinancialAssistance,patient support
US - Acalabrutinib - CO3_Support_FinancialAssistance,Acalabrutinib financial support 
US - Osimertinib - CI1_Contraindications,What are the contraindications for TAGRISSO?
US - Osimertinib - CI1_Contraindications,contraindicated
US - Osimertinib - CI1_Contraindications,contraindication
US - Osimertinib - CI1_Contraindications,What is TAGRISSO contraindicated for 
US - Durvalumab - DO3_Variations_DoseEscalation,Alternate dosing and dosing windows for Imfinzi® (durvalumab)
US - Durvalumab - DO3_Variations_DoseEscalation,imfinzi alternate dosing
US - Dato-dxd - CP2_MOA,What is the MOA of datopotamab deruxtecan?
US - Dato-dxd - CP2_MOA,Mechanism of Action
US - Dato-dxd - CP2_MOA,How does Dato-DXd work
US - Osimertinib - TE4_PreDrugUse_PlasmaTesting_EGFRm,Should plasma testing or tissue biopsy should be used for detecting EGFR mutations in patients with resectable NSCLC?
US - Osimertinib - TE4_PreDrugUse_PlasmaTesting_EGFRm,ctDNA in resectable NSCLC/early stage NSCLC
US - Olaparib - TE3_PreDrugUse_ctDNA,Do you have any data for circulating tumor DNA testing in prostate cancer? Lynparza
US - Olaparib - TE3_PreDrugUse_ctDNA,mCRPC ctDNA Lynparza
US - Olaparib - TE3_PreDrugUse_ctDNA,Plasma DNA Lynparza
US - Olaparib - TE3_PreDrugUse_ctDNA,Prostate cancer ctDNA Lynparza
US - Olaparib - TE3_PreDrugUse_ctDNA,results for ctDNA Lynparza
US - Olaparib - TE3_PreDrugUse_ctDNA,BRCA ctDNA Lynparza
US - Olaparib - TE3_PreDrugUse_ctDNA,ATM ctDNA Lynparza
US - Olaparib - TE3_PreDrugUse_ctDNA,FoundationOne Liquid CDxTM ctDNA test Lynparza
US - Olaparib - TE3_PreDrugUse_ctDNA,FoundationOne ctDNA test Lynparza
US - Olaparib - TE3_PreDrugUse_ctDNA,PROfound ctDNA
US - Olaparib - TE3_PreDrugUse_ctDNA,PROpel ctDNA
US - Durvalumab - DI1_DrugInteractions,Which drugs interact with Imfinzi® (durvalumab)?
US - Durvalumab - DI1_DrugInteractions,imfinzi drug interactions
US - Durvalumab - DI1_DrugInteractions,imfinzi di
US - Osimertinib - SS4_CONTACTPHARMAGROUP_ESMOCONGRESS_ESMOASIA2023,Tagrisso ESMO Asia
US - Osimertinib - SS4_CONTACTPHARMAGROUP_ESMOCONGRESS_ESMOASIA2023,Osimertinib ESMO Asia
US - Osimertinib - SS4_CONTACTPHARMAGROUP_ESMOCONGRESS_ESMOASIA2023,Tagrisso ESMO Asia 2023
US - Osimertinib - SS4_CONTACTPHARMAGROUP_ESMOCONGRESS_ESMOASIA2023,Osimertinib ESMO Asia 2023
US - Osimertinib - SS4_CONTACTPHARMAGROUP_ESMOCONGRESS_ESMOASIA2023,Tagrisso data from ESMO Asia 2023
US - Osimertinib - SS4_CONTACTPHARMAGROUP_ESMOCONGRESS_ESMOASIA2023,Osimertinib data from ESMO Asia 2023
US - Osimertinib - SS4_CONTACTPHARMAGROUP_ESMOCONGRESS_ESMOASIA2023,FLAURA2 ESMO Asia 2023
US - Osimertinib - SS4_CONTACTPHARMAGROUP_ESMOCONGRESS_ESMOASIA2023,FLAURA2 Safety-Run in ESMO Asia 2023
US - Osimertinib - SS4_CONTACTPHARMAGROUP_ESMOCONGRESS_ESMOASIA2023,FLAURA2 Safety Run-in Update ESMO Asia 2023
US - Osimertinib - SS4_CONTACTPHARMAGROUP_ESMOCONGRESS_ESMOASIA2023,FLAURA2 Resistance
US - Osimertinib - SS4_CONTACTPHARMAGROUP_ESMOCONGRESS_ESMOASIA2023,FLAURA2 Resistance ESMO Asia 2023
US - Osimertinib - SS4_CONTACTPHARMAGROUP_ESMOCONGRESS_ESMOASIA2023,FLAURA2 Acquired Mechanisms of Resistance ESMO Asia 2023
US - Dato-dxd - SA4_AdverseEvents_Oncology_Lung_Mucositis,What was the incidence of oral mucositis/stomatitis and mucosal inflammation in the NSCLC trial?
US - Dato-dxd - SA4_AdverseEvents_Oncology_Lung_Mucositis,Oral mucositis incidence in NSCLC 
US - Dato-dxd - SA4_AdverseEvents_Oncology_Lung_Mucositis,Stomatitis in NSCLC
US - Dato-dxd - SA4_AdverseEvents_Oncology_Lung_Mucositis,Mucosal inflammation incidence in NSCLC 
US - Osimertinib - RE3_PublishedData_ADAURA,ADAURA
US - Osimertinib - RE3_PublishedData_ADAURA,Tagrisso adjuvant setting
US - Osimertinib - RE3_PublishedData_ADAURA,Efficacy outcomes in ADAURA
US - Osimertinib - RE3_PublishedData_ADAURA,results in resectable NSCLC/adjuvant setting
US - Durvalumab - IN4_Resp_NSCLC_ResectableNSCLC,Imfinzi resectable NSCLC
US - Durvalumab - IN4_Resp_NSCLC_ResectableNSCLC,Imfinzi rNSCLC
US - Acalabrutinib - SA4_AdverseEvents_Heme_Bleeding,bleeding/hemorrhage rates with calquence  
US - Acalabrutinib - SA4_AdverseEvents_Heme_Bleeding,Can you provide me with data on bleeding/hemorrhage rates for acalabrutinib in patients with CLL/MCL?  
US - Acalabrutinib - SA4_AdverseEvents_Heme_Bleeding,acalabrutininb and bleeding
US - Acalabrutinib - SA4_AdverseEvents_Heme_Bleeding,acalabrutinib and hemorrhage
US - Acalabrutinib - SA4_AdverseEvents_Heme_Bleeding,major hemorrhage with calquence 
US - Acalabrutinib - SA4_AdverseEvents_Heme_Bleeding,Can you provide me with data on bleeding/hemorrhage rates for acalabrutinib in patients with CLL/MCL?
US - Osimertinib - IN1_IndicationsClinicalUse,What are the indications for Tagrisso® (osimertinib)?
US - Osimertinib - IN1_IndicationsClinicalUse,patient populations
US - Osimertinib - IN1_IndicationsClinicalUse,Who can take Tagrisso
US - Osimertinib - IN1_IndicationsClinicalUse,What is Tagrisso for
US - Osimertinib - IN1_IndicationsClinicalUse,Newly launched indication of Tagrisso
US - Osimertinib - IN1_IndicationsClinicalUse,Does Tagrisso PI indicate the use of Tagrisso with CTx?
US - Osimertinib - IN1_IndicationsClinicalUse,Osimertinib approval in new indication 
US - Durvalumab - IN3_Resp_SCLC,Use of Imfinzi® (durvalumab) in patients with SCLC
US - Durvalumab - IN3_Resp_SCLC,imfinzi sclc
US - Durvalumab - IN3_Resp_SCLC,imfinzi essclc
US - Durvalumab - IN3_Resp_SCLC,imfinzi es-sclc
US - Olaparib - EF4_ClinicalTrials_Duration Of Efficacy_LongTerm,Is there any data in patients receiving Lynparza for more than 2 years?
US - Olaparib - EF4_ClinicalTrials_Duration Of Efficacy_LongTerm,Lynparza/olaparib more than 2 years
US - Olaparib - EF4_ClinicalTrials_Duration Of Efficacy_LongTerm,Olaparib duration more than 2 years
US - Olaparib - EF4_ClinicalTrials_Duration Of Efficacy_LongTerm,Lynparza duration more than 2 years
US - Camizestrant - RE3_PublishedData_SERENA3,What is the trial design for SERENA-3
US - Camizestrant - RE3_PublishedData_SERENA3,SERENA-3 results
US - Camizestrant - RE3_PublishedData_SERENA3,SERENA-3 SABCS 2023
US - Olaparib - IN3_Heme_MDS,"In patients who developed myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), how long did patients receive Lynparza® (olaparib)?"
US - Olaparib - IN3_Heme_MDS,Lynparza time to onset of MDS/AML
US - Olaparib - IN3_Heme_MDS,Duration of Lynparza for MDS/AML
US - Olaparib - IN3_Heme_MDS,Duration of Lynparza with myelodysplastic syndrome/acute myeloid leukemia
US - Durvalumab - RE4_PublishedData_PACIFIC_Safety,What were the safety outcomes from PACIFIC?
US - Durvalumab - RE4_PublishedData_PACIFIC_Safety,imfinzi pacific safety
US - Olaparib - SA4_AdverseEvents_GIT_Pancreatic,What are the adverse events (AEs) in patients with pancreatic cancer receiving Lynparza® (olaparib)?
US - Osimertinib - EF3_ClinicalTrials_OS,Overall survival data for osimertinib therapy
US - Osimertinib - EF3_ClinicalTrials_OS,OS in ADAURA
US - Osimertinib - EF3_ClinicalTrials_OS,overall survival in ADAURA
US - Osimertinib - EF3_ClinicalTrials_OS,overall survival in adjuvant 
US - Osimertinib - EF3_ClinicalTrials_OS,overall survival in adjuvant setting
US - Osimertinib - EF3_ClinicalTrials_OS,OS in adjuvant setting
US - Osimertinib - EF3_ClinicalTrials_OS,OS in LAURA 
US - Osimertinib - EF3_ClinicalTrials_OS,OS in FLAURA 
US - Osimertinib - EF3_ClinicalTrials_OS,OS in FLAURA2
US - Acalabrutinib - DI3_Food_Grapefruit,Acalabrutinib interaction with orange drink
US - Acalabrutinib - DI3_Food_Grapefruit,calquence and grapefruit juice
US - Acalabrutinib - DI3_Food_Grapefruit,calquence and Seville oranges
US - Acalabrutinib - DI3_Food_Grapefruit,Do you have information on the interaction of acalabrutinib with Seville oranges/grapefruit juice?
US - Olaparib - RE3_PublishedData_PAOLA1,Paola-1 Trial
US - Olaparib - RE3_PublishedData_PAOLA1,Tell me about PAOLA-1 study
US - Olaparib - RE3_PublishedData_PAOLA1,PAOLA-1 study
US - Olaparib - RE3_PublishedData_PAOLA1,PAOLA-1 study results
US - Olaparib - RE3_PublishedData_PAOLA1,PAOLA-1 updated results
US - Olaparib - RE3_PublishedData_PAOLA1,PAOLA-1 update
US - Olaparib - RE3_PublishedData_PAOLA1,PAOLA-1 5 year update
US - Olaparib - RE3_PublishedData_PAOLA1,PAOLA-1 5 year data
US - Olaparib - RE3_PublishedData_PAOLA1,PAOLA-1 5 year results
US - Olaparib - RE3_PublishedData_PAOLA1,PAOLA-1 and ESMO GYN
US - Olaparib - RE3_PublishedData_PAOLA1,PAOLA-1 and ESMO GYN 2023 
US - Olaparib - EF4_ClinicalTrials_Reproduction_Ovarian_BRCA1,Is there a difference in efficacy in patients with BRCA1 vs. BRCA2 mutations?
US - Olaparib - EF4_ClinicalTrials_Reproduction_Ovarian_BRCA1,Difference in Lynparza efficacy in BRCA1 vs BRCA2 mutations
US - Olaparib - RE3_PublishedData_SOLO1,SOLO-1 trial
US - Olaparib - RE3_PublishedData_SOLO1,Tell me about the SOLO-1 study
US - Olaparib - RE3_PublishedData_SOLO1,SOLO-1 study
US - Olaparib - RE3_PublishedData_SOLO1,SOLO-1
US - Olaparib - RE3_PublishedData_SOLO1,SOLO-1 update
US - Olaparib - RE3_PublishedData_SOLO1,SOLO-1 7 year update
US - Olaparib - RE3_PublishedData_SOLO1,SOLO-1 7 year data
US - Olaparib - RE3_PublishedData_SOLO1,SOLO-1 7 year results
US - Olaparib - RE3_PublishedData_SOLO1,SOLO-1 long-term data
US - Olaparib - RE3_PublishedData_SOLO1,SOLO-1 long-term results
US - Acalabrutinib - IN3_Heme_MZL,Acalabrutinib in MZL
US - Acalabrutinib - IN3_Heme_MZL,Calquence in marginal zone lymphoma
US - Acalabrutinib - IN3_Heme_MZL,Calquence in MZL
US - Acalabrutinib - IN3_Heme_MZL,Acalabrutinib in ACE-LY-003
US - Acalabrutinib - IN3_Heme_MZL,Can acalabrutinib be used for patients with MZL?
US - Acalabrutinib - IN2_Renal,Calquence in renal impairment
US - Acalabrutinib - IN2_Renal,calquence in patients on dialysis?
US - Acalabrutinib - IN2_Renal,Acalabrutinib renal
US - Acalabrutinib - IN2_Renal,acalabrutinib and end stage renal disease
US - Acalabrutinib - IN2_Renal,calquence dose adjustments in patients with renal impairment
US - Acalabrutinib - IN2_Renal,Is Calquence indicated in renal impairment?
US - Acalabrutinib - IN2_Renal,What is the recommended dosing in patients with severe renal impairment (eGFR 
US - Acalabrutinib - IN2_Renal,Acalabrutinib and eGFR ≥ 30 mL/min
US - Osimertinib - DE2_Composition,What are the ingredients in Tagrisso
US - Osimertinib - DE2_Composition,ingredients
US - Osimertinib - DE2_Composition,Whats in Tagrisso
US - Osimertinib - DE2_Composition,Whats Tagrisso made out of
US - T-DXd - CO3_Support_Program,What are the support programs for Enhertu?
US - Olaparib - DO3_LateDose_MissedDose,Lynparza/olaparib missed dose
US - Olaparib - DO3_LateDose_MissedDose,What if patient misses dose of Lynparza/olaparib?
US - Olaparib - DO3_LateDose_MissedDose,Missing Lynparza/olaparib dose
US - Olaparib - RE4_PublishedData_PROpel_HRQoL,What are the health-related quality of life results from PROpel?
US - Olaparib - RE4_PublishedData_PROpel_HRQoL,PROpel health related QoL
US - Olaparib - RE4_PublishedData_PROpel_HRQoL,PROpel HRQoL
US - Olaparib - RE4_PublishedData_PROpel_HRQoL,PROpel hrqol
US - Olaparib - RE4_PublishedData_PROpel_HRQoL,PROpel health related outcome
US - Olaparib - EF4_ClinicalTrials_Combination_Abiraterone,Any data on olaparib and abiraterone combination therapy?
US - Olaparib - EF4_ClinicalTrials_Combination_Abiraterone,Study 8 data
US - Olaparib - EF4_ClinicalTrials_Combination_Abiraterone,Study 8 Efficacy
US - Olaparib - EF4_ClinicalTrials_Combination_Abiraterone,Study 8 Safety
US - Olaparib - EF4_ClinicalTrials_Combination_Abiraterone,olaparib and abiraterone combination efficacy
US - Olaparib - EF4_ClinicalTrials_Combination_Abiraterone,Study 8
US - Olaparib - EF4_ClinicalTrials_Combination_Abiraterone,olaparib+abiraterone combination efficacy
US - Olaparib - EF4_ClinicalTrials_Combination_Abiraterone,olaparib and abiraterone combination data
US - Olaparib - EF4_ClinicalTrials_Combination_Abiraterone,olaparib+abiraterone combination data
US - Olaparib - DI1_DrugInteractions,What drug interactions may occur with Lynparza?
US - Olaparib - DI1_DrugInteractions,What drug interactions may occur with olaparib?
US - Olaparib - DI1_DrugInteractions,Drug-Drug interactions with Lynparza/olaparib
US - Olaparib - DI1_DrugInteractions,Drug interactions with Lynparza/olaparib
US - Durvalumab - IN3_ID_COVID19,Use of Imfinzi® (durvalumab) in a COVID-19 positive patient/during COVID-19 pandemic?
US - Durvalumab - IN3_ID_COVID19,imfinzi covid19
US - Acalabrutinib - AD1_Administration,Calquence administration
US - Acalabrutinib - AD1_Administration,How is Calquence administered?
US - Acalabrutinib - AD1_Administration,Acalabrutinib administration
US - Acalabrutinib - AD1_Administration,Can the calquence tablets be broken
US - Acalabrutinib - AD1_Administration,Can the calquence capsules be opened
US - T-dxd - RE4_PublishedData_DESTINYLung01_OE,DESTINY-Lung01 HER2-overexpressing/OE/overexpression
US - T-dxd - RE4_PublishedData_DESTINYLung01_OE,DESTINY-Lung01 Cohorts 1 and 1a
US - T-dxd - RE4_PublishedData_DESTINYLung01_OE,"Apply all variations in the above utterances: Destiny-Lung 01, Destiny Lung 01, Destiny-Lung 1, Destiny Lung 1, DL-01, DL1, DL01, DL 1, DL 01"
US - Olaparib - IN2_Hepatic,Is Lynparza/olaparib indicated in hepatic impairment?
US - Olaparib - IN2_Hepatic,Olaparib/Lynparza hepatic impairment
US - Olaparib - IN2_Hepatic,Lynparza/olaparib liver impairment
US - Olaparib - IN2_Hepatic,Lynparza/olaparib in liver disease
US - Olaparib - IN2_Hepatic,Lynparza/olaparib in hepatic disease
US - Durvalumab - RE3_PUBLISHEDDATA_AEGEAN,Imfinzi AEGEAN
US - Durvalumab - RE3_PUBLISHEDDATA_AEGEAN,Imfinzi AEGEAN AACR
US - Durvalumab - RE3_PUBLISHEDDATA_AEGEAN,Imfinzi AEGEAN AACR 2023
US - Durvalumab - RE3_PUBLISHEDDATA_AEGEAN,AACR AEGEAN
US - Durvalumab - RE3_PUBLISHEDDATA_AEGEAN,AACR AEGEAN Imfinzi
US - Durvalumab - RE3_PUBLISHEDDATA_AEGEAN,Imfinzi AACR AEGEAN
US - Durvalumab - RE3_PUBLISHEDDATA_AEGEAN,Imfinzi AEGEAN ASCO
US - Durvalumab - RE3_PUBLISHEDDATA_AEGEAN,IMFINZI WCLC 2023 
US - Durvalumab - RE3_PUBLISHEDDATA_AEGEAN,ELCC 2024 AEGEAN
US - Durvalumab - RE3_PUBLISHEDDATA_AEGEAN,ELCC AEGEAN
US - Durvalumab - RE3_PUBLISHEDDATA_AEGEAN,Imfinzi AEGEAN ELCC
US - Osimertinib - ST1_StorageStability,Are there any special instructions for handling Osimertinib?
US - Osimertinib - ST1_StorageStability,"MSDS, OSHA"
US - Osimertinib - ST1_StorageStability,storing tagrisso
US - Osimertinib - ST1_StorageStability,safe handling of tagrisso
US - Osimertinib - ST1_StorageStability,stability of tagrisso
US - Osimertinib - ST1_StorageStability,Preserving osimertinib
US - Osimertinib - ST1_StorageStability,Saving osimertinib
US - T-DXd - CP2_MOA,What is the MOA of Enhertu?
US - Durvalumab - AD3_Instructions_HomeInfusionSetting,Can Imfinzi® (durvalumab) be given in a home infusion setting?
US - Durvalumab - AD3_Instructions_HomeInfusionSetting,imfinzi home infusion
US - Capivasertib - ST1_STORAGESTABILITY,Capivasertib storage
US - Capivasertib - ST1_STORAGESTABILITY,Capivasertib supply
US - Capivasertib - ST1_STORAGESTABILITY,Capivasertib stability
US - Capivasertib - ST1_STORAGESTABILITY,Capivasertib temperature
US - Capivasertib - ST1_STORAGESTABILITY,Capivasertib temperature excursions
US - Capivasertib - ST1_STORAGESTABILITY,TRUQAP storage
US - Capivasertib - ST1_STORAGESTABILITY,TRUQAP supply
US - Capivasertib - ST1_STORAGESTABILITY,TRUQAP stability
US - Capivasertib - ST1_STORAGESTABILITY,TRUQAP temperature
US - Capivasertib - ST1_STORAGESTABILITY,TRUQAP temperature excursions
US - Olaparib - SS3_ContactPharmaGroup_ESMOCongress,lynparza ESMO
US - Olaparib - SS3_ContactPharmaGroup_ESMOCongress,ESMO Lynparza
US - Olaparib - SS3_ContactPharmaGroup_ESMOCongress,ESMO 2022 Lynparza
US - Olaparib - SS3_ContactPharmaGroup_ESMOCongress,ESMO Congress lynparza
US - Olaparib - SS3_ContactPharmaGroup_ESMOCongress,ESMO Congress 2022 lynparza
US - Olaparib - SS3_ContactPharmaGroup_ESMOCongress,Olaparib ESMO
US - Olaparib - SS3_ContactPharmaGroup_ESMOCongress,ESMO Olaparib
US - Olaparib - SS3_ContactPharmaGroup_ESMOCongress,ESMO 2022 Olaparib
US - Olaparib - SS3_ContactPharmaGroup_ESMOCongress,ESMO Congress Olaparib
US - Olaparib - SS3_ContactPharmaGroup_ESMOCongress,ESMO Congress 2022 Olaparib
US - Durvalumab - RE4_PublishedData_PACIFIC_Chemoradiation,What were the prior chemoradiation therapy regimens in PACIFIC?
US - Durvalumab - RE4_PublishedData_PACIFIC_Chemoradiation,prior chemoradiotherapy pacific
US - Durvalumab - DE1_Description,Tell me about Imfinzi
US - Durvalumab - DE1_Description,durva
US - Durvalumab - DE1_Description,infinzi
US - Durvalumab - DE1_Description,infimzi
US - T-DXd - SA3_AdverseEvents_MostCommon,What are the most common adverse reactions with Enhertu?
US - T-DXd - SA3_AdverseEvents_MostCommon,common adverse events with Enhertu
US - Olaparib - RE3_PublishedData_SOLO3,SOLO-3 trial
US - Olaparib - RE3_PublishedData_SOLO3,SOLO-3 Dear HCP letter
US - Olaparib - RE3_PublishedData_SOLO3,Lynparza Dear HCP letter
US - Olaparib - RE3_PublishedData_SOLO3,SOLO-3 OS results
US - Olaparib - RE3_PublishedData_SOLO3,SOLO-3 Overall Survival
US - Olaparib - RE3_PublishedData_SOLO3,SOLO-3 post-hoc analysis
US - Acalabrutinib - IN3_Reproduction_Pregnancy,Calquence in pregnancy
US - Acalabrutinib - IN3_Reproduction_Pregnancy,acalabrutinib in pregnancy
US - Acalabrutinib - IN3_Reproduction_Pregnancy,Acalabrutinib in pregnant patients
US - Acalabrutinib - IN3_Reproduction_Pregnancy,acalabrutinib effect on fetus
US - Acalabrutinib - IN3_Reproduction_Pregnancy,Is Calquence indicated in pregnant patients?  
US - Acalabrutinib - IN3_Reproduction_Pregnancy,Can Calquence® (acalabrutinib) be used in pregnant patients?
US - Durvalumab - RE4_PublishedData_DUO-O_Safety,DUO-O safety
US - Durvalumab - RE4_PublishedData_DUO-O_Safety,Safety of DUO-O
US - Durvalumab - RE4_PublishedData_DUO-O_Safety,DUO-O safety results
US - Durvalumab - RE4_PublishedData_DUO-O_Safety,What is the safety results of DUO_O study
US - Durvalumab - RE2_ParticipationOpportunity,Enrollment in Imfinzi® (durvalumab) clinical trials?
US - Durvalumab - RE2_ParticipationOpportunity,imfinzi enrollment
US - Olaparib - RE4_PublishedData_PROfound_Safety,What are the safety results of PROfound?
US - Olaparib - RE4_PublishedData_PROfound_Safety,Profound safety
US - Olaparib - RE4_PublishedData_PROfound_Safety,profound safety results
US - Olaparib - RE4_PublishedData_PROfound_Safety,profound adverse events
US - Olaparib - RE4_PublishedData_PROfound_Safety,PROfound AE
US - Olaparib - RE4_PublishedData_PROfound_Safety,AE PROfound
US - Olaparib - SA4_AdverseEvents_Heme_MDS,What is the updated incidence of myelodysplastic syndrome (MDS) with Lynparza?
US - Olaparib - SA4_AdverseEvents_Heme_MDS,What is the updated incidence of acute myeloid leukemia (AML) with Lynparza?
US - Olaparib - SA4_AdverseEvents_Heme_MDS,What is the rate of MDS/AML in Lynparza?
US - Olaparib - SA4_AdverseEvents_Heme_MDS,What is the rate of MDS/AML in Olaparib?
US - Olaparib - SA4_AdverseEvents_Heme_MDS,Lynparza acute myeloid leukemia/AML
US - Olaparib - SA4_AdverseEvents_Heme_MDS,Lynparza myelodysplastic syndrome/MDS
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate,What is the efficacy of Lynparza in prostate cancer?
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate,olaparib trials in prostate
US - Olaparib - EF4_ClinicalTrials_Reproduction_Prostate,olaparib efficacy in prostate
US - Durvalumab - RE4_OngoingStudies_TOPAZ1_Safety,What were the safety outcomes from TOPAZ
US - Durvalumab - RE4_OngoingStudies_TOPAZ1_Safety,safety results for TOPAZ-1
US - Durvalumab - RE4_OngoingStudies_TOPAZ1_Safety,safety data for topaz-1
US - Durvalumab - RE4_OngoingStudies_TOPAZ1_Safety,Adverse event results/data for Topaz
US - Durvalumab - RE4_OngoingStudies_TOPAZ1_Safety,AE results/data from Topaz
US - Durvalumab - RE4_OngoingStudies_TOPAZ1_Safety,Adverse reactions in Topaz
US - Olaparib - SA2_AEManagement,What should be done in the case of an adverse event? Lynparza
US - Olaparib - SA2_AEManagement,Management of Lynparza Adverse Events
US - Olaparib - SA2_AEManagement,Management of Lynparza AEs
US - Olaparib - SA2_AEManagement,Lynparza AE managment
US - Olaparib - SA2_AEManagement,Managing Lynparza adverse events
US - Olaparib - SA2_AEManagement,Managing lynparza AEs
US - Olaparib - SA2_AEManagement,Management of nausea lynparza
US - Osimertinib - SS3_ContactPharmaGroup_Samples,Can I order samples of Tagrisso® (osimertinib)?
US - Durvalumab - RE3_PublishedData_MEDIOLA,Tell me about the MEDIOLA study
US - Durvalumab - RE3_PublishedData_MEDIOLA,MEDIOLA
US - Durvalumab - RE3_PublishedData_MEDIOLA,MEDIOLA study
US - Durvalumab - RE3_PublishedData_MEDIOLA,Durvalumab and olaparib in ovarian cancer
US - Durvalumab - RE3_PublishedData_MEDIOLA,Imfinzi and Lynparza in ovarian cancer
US - Durvalumab - RE3_PublishedData_MEDIOLA,MEDIOLA study results
US - Durvalumab - RE3_PublishedData_MEDIOLA,MEDIOLA results
US - Durvalumab - RE3_PublishedData_MEDIOLA,Olaparib and durvalumab
US - Durvalumab - RE3_PublishedData_MEDIOLA,Imfinzi and Lynparza
US - Durvalumab - RE3_PublishedData_MEDIOLA,Lynparza and Imfinzi
US - Durvalumab - RE3_PublishedData_MEDIOLA,Durvalumab and olaparib
US - Durvalumab - RE3_PublishedData_MEDIOLA,Olaparib and durvalumab in ovarian cancer
US - Durvalumab - RE3_PublishedData_MEDIOLA,Durvalumab and olaparib in ovarian cancer
US - Durvalumab - RE3_PublishedData_NeoCOAST,NeoCOAST
US - Olaparib - SA3_AdverseEvents_MostCommon,What are the most common adverse events? Lynparza
US - Olaparib - SA3_AdverseEvents_MostCommon,Lynparza/olaparib adverse events
US - Olaparib - SA3_AdverseEvents_MostCommon,Lynparza/olaparib AEs
US - Olaparib - SA3_AdverseEvents_MostCommon,What are the most common adverse events with Lynparza/olaparib?”
US - Olaparib - SA3_AdverseEvents_MostCommon, Lynparza/olaparib most common AEs
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,Can I use Osimertinib with a MET inhibitor?
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,combination/coadministration with MET inhibitor/savolitinib
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,Tagrisso with MET inhibitors
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,Can you provide info on MET inhibitor and drug DI
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,Provide me information related to MET inhibitor and Tagrisso DI
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,Can there be any possible Tagrisso DI MET inhibitor
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,What can you tell me about Tagrisso DI with MET inhibitor
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,Drug interactions and METInhibitors
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,METInhibitors and Drug interactions
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,Can you provide info on METInhibitors and drugx interactions
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,Provide me information related to METInhibitors and drugx interactions
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,Can there be any possible drugx interactions with METInhibitors
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,Any possible drugx interactions with METInhibitors
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,Help me know about drugx interactions and METInhibitors
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,What can you tell me about drugx interactions with METInhibitors
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,Help me know about drugx interactions with METInhibitors
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,Are there any possible drugx interactions with METInhibitors
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,I am interested to know about drugx and METInhibitors interactions
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,I am curious to know about drugx and METInhibitors interactions
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,May i have information on drugx and METInhibitors interactions
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,Info on drugx and METInhibitors interactions
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,Drugx and METInhibitors interactions
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,Explain about drugx interactions with METInhibitors
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,What can you explain about drugx interactions with METInhibitors
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,Give me explaination on drugx and METInhibitors interactions
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,Does drugx have any possible interactions with METInhibitors
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,Let me know about drugx interactions with METInhibitors
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,Let me know about any possible drugx interactions with METInhibitors
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,What drugx interactions are possible with METInhibitors
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,What interactions are possible between drugx METInhibitors
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,I am interested to know about interactions between drugx and METInhibitors
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,Tell me about possible interactions between drugx METInhibitors
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,Drug interactions METInhibitors
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,METInhibitors Drug interactions
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,Tagrisso combination/coadministration with met inhibitors/savoltitinib
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,combination/coadministration with met inhibitors/savoltitinib Tagrisso
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,combination with MET inhibitors
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,tagrisso combination with MET inhibitors
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,combination with MET inhibitors tagrisso
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,coadministration with MET inhibitors
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,tagrisso coadministration with MET inhibitors
US - Osimertinib - IN3 - PlaceInTherapy_METInhibitors,coadministration with MET inhibitors tagrisso
US - Durvalumab- SS4_HCPSupport_Resources_PrescribingInformation,Are you asking for the Imfinzi® (durvalumab) Prescribing Information?
US - Durvalumab- SS4_HCPSupport_Resources_PrescribingInformation,imfinzi pi
US - Durvalumab- SS4_HCPSupport_Resources_PrescribingInformation,imfinzi prescribing information
US - Durvalumab- SS4_HCPSupport_Resources_PrescribingInformation,imfinzi package insert
US - Durvalumab- SS4_HCPSupport_Resources_PrescribingInformation,Please display Imfinzi PI
US - Durvalumab- SS4_HCPSupport_Resources_PrescribingInformation,Can I please see the Imfinzi PI link
US - Durvalumab- SS4_HCPSupport_Resources_PrescribingInformation,Please provide the link to the Imfinzi PI
US - Durvalumab- SS4_HCPSupport_Resources_PrescribingInformation,Link to the package insert for durvalumab
US - Durvalumab- SS4_HCPSupport_Resources_PrescribingInformation,Please show the prescribing information for durvalumab
US - Durvalumab - RE4_PublishedData_PACIFIC_Pneumonitis,What was the occurrence of pneumonitis with Imfinzi® (durvalumab) in PACIFIC?
US - Durvalumab - RE4_PublishedData_PACIFIC_Pneumonitis,imfinzi pacific pneumonitis
US - T-DXd - IN3_CNS_Metastasis,Use of Enhertu in CNS metastasesAre there any data with Enhertu/T-DXd in patients with brain mets?    
US - T-DXd - IN3_CNS_Metastasis,Are there any data with Enhertu/T-DXd in patients with brain mets?
US - T-DXd - IN3_CNS_Metastasis,Are there any data with Enhertu/T-DXd in patients with active brain metastases?
US - T-DXd - IN3_CNS_Metastasis, Are there any data with Enhertu/T-DXd in patients with brain metastases?
US - T-DXd - IN3_CNS_Metastasis,Does Enhertu/T-DXd penetrate the CNS?
US - T-DXd - IN3_CNS_Metastasis,What is the mechanism of antibody-drug conjugates penetrating the blood-brain barrier in patients with CNS metastases?  
US - T-DXd - IN3_CNS_Metastasis,Does Enhertu/T-DXd cross the blood-brain barrier?       
US - Capivasertib - CAPITELLO-291 EFFICACY,What are the most common AEs in Capitello-291?
US - Capivasertib - CAPITELLO-291 EFFICACY,What are the most common AEs in Capitello-291?
US - Capivasertib - CAPITELLO-291 EFFICACY,What are the AEs with capivasertib?
US - Capivasertib - CAPITELLO-291 EFFICACY,Safety of capivasertib?
US - Capivasertib - CAPITELLO-291 EFFICACY,Most common AEs with capivasertib?
US - Capivasertib - CAPITELLO-291 EFFICACY,Capitello-291 safety profile 
US - Tremelimumab - DO1_Dosing,what is recommended dosage for tremelimumab  
US - Tremelimumab - DO1_Dosing,What dosing has been used in clinical trials
US - Tremelimumab - DO1_Dosing,how is treme administered
US - Tremelimumab - DO1_Dosing,"Dosage of treme, administration of treme"
US - Olaparib - IN3_Subgroup_Pediatrics,Is Lynparza indicated in pediatric patients?
US - Olaparib - IN3_Subgroup_Pediatrics,Use of Lynparza in children
US - Olaparib - IN3_Subgroup_Pediatrics,Use of Lynparza in pediatric patients
US - Olaparib - IN3_Subgroup_Pediatrics,Lynparza in pediatric patients
US - Olaparib - IN3_Subgroup_Pediatrics,Lynparza in children
US - Olaparib - IN3_Subgroup_Pediatrics,Is olaparib indicated in pediatric patients?
US - Olaparib - IN3_Subgroup_Pediatrics,Use of olaparib in children
US - Olaparib - IN3_Subgroup_Pediatrics,Use of olaparib in pediatric patients
US - Olaparib - IN3_Subgroup_Pediatrics,olaparib in pediatric patients
US - Olaparib - IN3_Subgroup_Pediatrics,olaparib in children
US - Durvalumab - SS3_CONTACTPHARMAGROUP_ELCC2024,IMFINZI results from ELCC 2024
US - Durvalumab - SS3_CONTACTPHARMAGROUP_ELCC2024,durvalumab results from ELCC 2024
US - Durvalumab - SS3_CONTACTPHARMAGROUP_ELCC2024,ELCC 2024 PACIFIC2
US - Durvalumab - SS3_CONTACTPHARMAGROUP_ELCC2024,ELCC PACIFIC2
US - Durvalumab - SS3_CONTACTPHARMAGROUP_ELCC2024,ELCC 2024 PACIFIC 2
US - Durvalumab - SS3_CONTACTPHARMAGROUP_ELCC2024,ELCC PACIFIC 2
US - Durvalumab - SS3_CONTACTPHARMAGROUP_ELCC2024,ELCC 2024 PAC2
US - Durvalumab - SS3_CONTACTPHARMAGROUP_ELCC2024,ELCC PAC2
US - Durvalumab - SS3_CONTACTPHARMAGROUP_ELCC2024,Imfinzi PACIFIC2 ELCC
US - Durvalumab - SS3_CONTACTPHARMAGROUP_ELCC2024,Imfinzi PACIFIC 2 ELCC
US - Durvalumab - SS3_CONTACTPHARMAGROUP_ELCC2024,Imfinzi PAC2 ELCC
US - Durvalumab - SS3_CONTACTPHARMAGROUP_ELCC2024,CORRELATE study
US - Durvalumab - SS3_CONTACTPHARMAGROUP_ELCC2024,CORRELATE study results
US - Durvalumab - SS3_CONTACTPHARMAGROUP_ELCC2024,CORRELATE study data
US - Durvalumab - SS3_CONTACTPHARMAGROUP_ELCC2024,ELCC 2024 CORRELATE
US - Durvalumab - SS3_CONTACTPHARMAGROUP_ELCC2024,ELCC CORRELATE
US - Durvalumab - SS3_CONTACTPHARMAGROUP_ELCC2024,Imfinzi CORRELATE ELCC
US - Durvalumab - SS3_CONTACTPHARMAGROUP_ELCC2024,Imfinzi CORRELATE results ELCC
US - Durvalumab - SS3_CONTACTPHARMAGROUP_ELCC2024,CORRELATE results ELCC
US - Durvalumab - SS3_CONTACTPHARMAGROUP_ELCC2024,IMFINZI ELCC
US - Durvalumab - SS3_CONTACTPHARMAGROUP_ELCC2024,IMFINZI ELCC 2024
US - Durvalumab - SS3_CONTACTPHARMAGROUP_ELCC2024,IMFINZI data from ELCC 2024
US - Durvalumab - SS3_CONTACTPHARMAGROUP_ELCC2024,Durvalumab ELCC
US - Durvalumab - SS3_CONTACTPHARMAGROUP_ELCC2024,Durvalumab ELCC 2024
US - Durvalumab - SS3_CONTACTPHARMAGROUP_ELCC2024,Durvalumab data from ELCC 2024
US - Olaparib - RE4_PUBLISHEDDATA_DUO-O_SAFETY,DUO-O ssafety
US - Olaparib - RE4_PUBLISHEDDATA_DUO-O_SAFETY,Safety of DUO-O
US - Olaparib - RE4_PUBLISHEDDATA_DUO-O_SAFETY,DUO-O safety results
US - Olaparib - RE4_PUBLISHEDDATA_DUO-O_SAFETY,What is the safety results of DUO_O study
US - Osimertinib - SS4_CONTACTPHARMAGROUP_ESMOCONGRESS_ESMO2023,Osimertinib ESMO 2023
US - Osimertinib - SS4_CONTACTPHARMAGROUP_ESMOCONGRESS_ESMO2023,Tagrisso data from ESMO 2023
US - Osimertinib - SS4_CONTACTPHARMAGROUP_ESMOCONGRESS_ESMO2023,Osimertinib data from ESMO 2023
US - Osimertinib - SS4_CONTACTPHARMAGROUP_ESMOCONGRESS_ESMO2023,OCELOT ESMO 2023
US - Osimertinib - SS4_CONTACTPHARMAGROUP_ESMOCONGRESS_ESMO2023,OCELOT interim analysis data from ESMO 2023
US - Osimertinib - SS4_CONTACTPHARMAGROUP_ESMOCONGRESS_ESMO2023,RWE study data of LTS from ESMO 2023
US - Osimertinib - SS4_CONTACTPHARMAGROUP_ESMOCONGRESS_ESMO2023,FLAURA2 ESMO 2023
US - Osimertinib - SS4_CONTACTPHARMAGROUP_ESMOCONGRESS_ESMO2023,Tagrisso ESMO 2023
US - Osimertinib - SS4_CONTACTPHARMAGROUP_ESMOCONGRESS_ESMO2023,tagrisso ESMO
